[PDF]3 01-05-2018 Class I IgG.xlsx - Rackcdn.comhttps://75c17d9f6eecafb09b78-695e1a25d6559f5c6a6714b54be309d0.ssl.cf3.rackcdn.c...
2 downloads
116 Views
390KB Size
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A1 Consensus Present 95.9% % reported Lab no. spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A1 A1 A1 A1 A1 A1 A1 A1 A1
L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
A1 A1 A1 A1 A1 A1 A1
L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000
A2 Absent 1.4% spec
tech
MFI
A203 Absent 1.4% spec
tech
MFI
> 5000 > 5000 > 5000 A2
F
> 5000
A203
L
A3 Present 94.5% spec
tech
MFI
A23 Not Assessed 72.6% spec
A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3
L L L L L L L L L L L L L L L L L C, L L L L L L L L L L L L L L L C, L L L L L L L L L L L L L L L C, L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A3 A3 A3
L L L
A3 A3 A3 A3 A3
L L L L L
> 5000 > 5000 A23 > 5000 A23 > 5000 > 5000 A23 > 5000 A23 > 5000 A23 > 5000 A23
A3 A3 A3 A3 A3 A3 A3
L L L L L L L
> 5000 > 5000 > 5000 > 5000 A23 > 5000 A23 > 5000 A23 > 5000
MFI
A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23
L L L L L L L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000
A23
L
2000-5000
A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23
L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000
A23 A23 A23 A23 A23 A23
L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000
A23 A23
L L
2000-5000 2000-5000
A23
L
2000-5000
A23 A23 A23 A23
A23 > 5000 A23
> 5000
tech
A24 Present 94.5% spec
tech
MFI
A2403 Not Assessed 56.2% spec
tech
MFI
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L L L L
> 5000 > 5000 > 5000 > 5000
A2403 A2403 A2403 A2403 A2403 A2403 A2403
L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A2403 A2403 A2403 A2403 A2403 A2403 A2403 A2403
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A2403 A2403 A2403 A2403 A2403
L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000
A2403
L
> 5000
A2403 A2403
L L
> 5000 > 5000
A2403 A2403
L L
> 5000 > 5000
A2403
2000-5000 2000-5000 > 5000 2000-5000
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
A2403 A2403 A2403 A2403
L L L L
A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24
A2403 A2403 A2403
L L L F L
> 5000 > 5000 > 5000
A2403 A2403
F L
A24 A24 A24 A24 2000-5000 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24
L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A24 A24 A24 2000-5000 A24 < 2000 A24 2000-5000 A24 A24
L L L L L L L
> 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000
L
2000-5000
L
> 5000
L L L L
L L L
2000-5000 2000-5000 2000-5000 2000-5000
A25 Present 89.0% spec
tech
MFI
A26 Not Assessed 61.6% spec
tech
MFI
2000-5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
L L L L L
< 2000 < 2000 2000-5000 < 2000 2000-5000
A26 A26 A26 A26 A26 A26 A26 A26 A26 A26
L L L L L L L L L L
2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000
A26 A26
L L
< 2000 2000-5000
A26 A26 A26
L L L
2000-5000 2000-5000 2000-5000
A26
L
< 2000
A26 A26 A26 A26 A26
> 5000
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
A26 A26 A26 A26 A26
L
A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25
L L L
L
> 5000 A25 > 5000 A25 > 5000 A25 A25 A25 A25 A25 > 5000 A25
L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000
L
> 5000 A25 A25 A25 A25 > 5000 A25
> 5000
A2403
L
A2403
L
A2403
L
A2403
L
A2403
L
A2403
L
A34 Present 79.5% spec
tech
MFI
L L L L L
< 2000 < 2000 < 2000 > 5000 < 2000
A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000, 2000-5000 2000-5000 < 2000, 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000, > 5000 2000-5000
A26 A26
L L
A26 A26 A26
L L L
A26
L
2000-5000 A34 2000-5000 A34 A34 < 2000 A34 < 2000 A34 < 2000 A34 A34 < 2000 A34 A34
L L L L L L L L L
2000-5000 2000-5000 > 5000 < 2000, 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
A26
L
< 2000
A34
L
< 2000
A26 A26
L L
< 2000 < 2000
A34 A34
L L
2000-5000 2000-5000
A26 A26
L L
< 2000 > 5000
A34 A34 A34
L L L
2000-5000 > 5000 < 2000
F L
2000-5000 A26
L
< 2000
A34
L
2000-5000
L L L
2000-5000 A26 2000-5000 < 2000
L
> 5000 A34 A34
L L
< 2000 < 2000
> 5000 A25 A25 > 5000 A25 A25 A25
L L L L L
< 2000 2000-5000 2000-5000 A26 2000-5000 A26 2000-5000 A26
A34 A34 A34 A34 A34 A34
L L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
A25 > 5000 A25
L L
2000-5000 < 2000
A25 < 2000 A25 A25 > 5000 A25
L L L L
2000-5000 A26 < 2000 A26 2000-5000 A26 < 2000
A34 A34 A34
L L L
2000-5000 < 2000 2000-5000
L L L
< 2000 < 2000 < 2000
L L L
< 2000 < 2000 < 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other Number Total number
70 73
< 2000 0 2000-5000 4 > 5000 64
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 1
69 73
< 2000 0 2000-5000 0 > 5000 68
53 73
< 2000 4 2000-5000 40 > 5000 8
69 73
< 2000 2 2000-5000 1 > 5000 65
41 73
< 2000 1 2000-5000 0 > 5000 40
65 73
< 2000 13 2000-5000 46 > 5000 5
45 73
< 2000 31 2000-5000 11 > 5000 3
58 73
< 2000 10 2000-5000 41 > 5000 4
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 1 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A66 Conse Present % rep 90.4% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000, > 5000 > 5000 < 2000, > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000, > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000
A66 A66 A66 A66
L L L L
2000-5000 2000-5000 2000-5000 > 5000
A66 A66 A66
L L L
2000-5000 > 5000 > 5000
A66 A66 A66
L F L
> 5000
A66 A66
L L
2000-5000 2000-5000
A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66
L L L L L L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000
A11 Present 93.2% spec
tech
MFI
A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A11 A11
A29 Present 89.0% spec
tech
MFI
A30 Present 90.4% spec
tech
MFI
A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 > 5000 > 5000 2000-5000, > 5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000
A29 A29 A29 A29
L L L L
2000-5000 < 2000 2000-5000 2000-5000
A30 A30 A30 A30
L L L L
A29 A29 A29
L L L
2000-5000 2000-5000 < 2000
A30
A29 A29 > 5000 A29
L F L
< 2000
F L
A30 A30 A30 A30 A30
A11 A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A29 A29 A29 A29 A29 A29 A29 A29
L L L L L L L L
2000-5000 < 2000 > 5000 < 2000 2000-5000 > 5000 2000-5000 2000-5000
A11 A11
L L
> 5000 A29 > 5000 A29
L L
2000-5000 < 2000
A11 A11 A11 A11
L L L L
> 5000 > 5000 > 5000 > 5000
L L L L
2000-5000 2000-5000 > 5000 < 2000
A29 A29 A29 A29
> 5000
A31 Present 90.4% spec
tech
MFI
> 5000 < 2000 > 5000 > 5000
A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000
L
> 5000
A31
L
> 5000
L L L F L
2000-5000 A31 > 5000 2000-5000 A31 A31 > 5000 A31
L
< 2000
L F L
< 2000
A30 A30 A30 A30 A30 A30 A30 A30
L L L L L L L L
A31 2000-5000 A31 2000-5000 A31 > 5000 A31 < 2000 A31 > 5000 A31 > 5000 A31 > 5000 A31 > 5000 A31
A30 A30 A30 A30 A30 A30 A30
L L L L L L L
> 5000 < 2000 2000-5000 > 5000 2000-5000 > 5000 < 2000
A31 A31 A31 A31 A31 A31 A31
A32 Present 93.2% spec
tech
A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L C, L L L L L L L L L L L L L L L L
> 5000
A32 A32 A32 A32 A32
L L L L L L L L L
> 5000 2000-5000 < 2000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000
L L L L L L L
> 5000 < 2000 > 5000 > 5000 < 2000 > 5000 < 2000
MFI > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000
A33 Present 83.6% spec
tech
MFI
A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000
A33 A33 A33 A33 A33 A33 A33 A33
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000
A33 A33 A33 A33
L L L F L
A33 A33 2000-5000 > 5000 2000-5000 A33 A33 > 5000 A33
A32 A32 A32 A32 A32 A32 A32 A32 A32
L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
A33 A33 A33 A33 A33 A33 A33 A33
L L L L L L ; L
< 2000 < 2000 > 5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
A32 A32
L L
A32 A32 A32 A32
L L L L
> 5000 2000-5000 A33 A33 > 5000 A33 2000-5000 A33 > 5000 A33 2000-5000
L L L L L
< 2000 > 5000 2000-5000 < 2000 2000-5000
> 5000
A74 Present 90.4% spec
tech
MFI
L L L L
2000-5000 < 2000 2000-5000 2000-5000
A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74 A74
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000
L L
2000-5000 A74 > 5000 A74 A74
L L L
> 5000 2000-5000 2000-5000
L F L
< 2000
A74 A74 2000-5000 A74
L F L
2000-5000
A74 A74 A74
L L L
2000-5000 > 5000 2000-5000
A74 A74 A74 A74 A74
L L L L L
< 2000 > 5000 > 5000 > 5000 > 5000
A74 A74
L L
> 5000 < 2000
A74 A74 A74 A74
L L L L
> 5000 2000-5000 > 5000 < 2000
A68 Absent 1.4% spec
A68
tech
F
MFI
A69 Absent 4.1% spec
tech
A69
L
A69
F
A69
L
MFI
2000-5000
> 5000 2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 66 73
< 2000 0 2000-5000 17 > 5000 47
68 73
< 2000 0 2000-5000 0 > 5000 67
65 73
< 2000 11 2000-5000 34 > 5000 19
66 73
< 2000 6 2000-5000 12 > 5000 47
66 73
< 2000 12 2000-5000 3 > 5000 51
68 73
< 2000 0 2000-5000 11 > 5000 55
61 73
< 2000 11 2000-5000 45 > 5000 4
66 73
< 2000 4 2000-5000 10 > 5000 51
1 73
< 2000 0 2000-5000 0 > 5000 0
3 73
< 2000 0 2000-5000 2 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 2 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A36 A43 Not Assessed Conse Present 52.1% % rep 93.2% tech MFI spec Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
A36 A36 A36
L L L
> 5000 > 5000 > 5000
A36 A36 A36 A36 A36
L L L L L
> 5000 > 5000 > 5000 A43 > 5000 A43 > 5000 A43
A36 A36
L L
> 5000 > 5000
A36 A36 A36 A36
L L L L
> 5000 A43 > 5000 A43 > 5000 A43 > 5000
tech
MFI
A43 A43 A43 A43 A43
L L L L L
< 2000 < 2000 2000-5000 < 2000 2000-5000
A43
L
2000-5000
A43 A43 A43 A43 A43 A43
L L L L L L
< 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000
A43
L
< 2000
A43 A43
L L
< 2000 < 2000
A43 A43 A43
L L L
2000-5000 < 2000 2000-5000
A43
L
< 2000
A43
L
< 2000
A43 A43 A43
L L L
< 2000 2000-5000 < 2000
A43 A43
L L
2000-5000 < 2000
A43
L
< 2000
A43
L
< 2000
A43
L
< 2000
A43 A43
L L
< 2000 < 2000
A43
L
2000-5000
> 5000 A43
L
L L L
L L L
A80 Present 93.2% spec
tech
MFI
B51 Not Assessed 5.5% spec
A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 B51 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A80 A80
F L
> 5000
A80 A80 A80
L L L
> 5000 > 5000 > 5000
A80 A80 2000-5000 A80 < 2000 A80 < 2000 A80 A80 A80 A80
L L L L L L L L
< 2000 < 2000 < 2000
L L L L
< 2000
A80 A80 A80 A80
tech
MFI
B5102 Absent 1.4% spec
tech
MFI
B52 Not Assessed 5.5% spec
tech
MFI
B7 Present 95.9% spec
tech
MFI
B703 Not Assessed 16.4% spec
B7 B7 < 2000 B7 B7 B7 B7 B7 B7 B7 B7 B7 < 2000 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7
L L L L L L L L L L L L L L L L L C, L L L L L L L L L L L L L L L C, L L L L L L L L L L L L L L L C, L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
> 5000 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7
L L L L L L L L L L L L
> 5000 > 5000 > 5000 B703 > 5000 > 5000 B703 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 B703
> 5000 > 5000 > 5000 2000-5000
B7 B7 B7 B7
L L L L
> 5000 > 5000 B703 > 5000 > 5000 B703
L
< 2000 B5102
L
< 2000 B52
L
B52
B51
F
L
B52
B51
L
> 5000
B51
L
> 5000
F
B52
L
B703
B703 B703
tech
L
L L
MFI
B8 Not Assessed 27.4% spec
tech
MFI
B8
L
< 2000
B8
L
< 2000
B8
L
< 2000
B8
L
> 5000
B8
L
< 2000
> 5000 B8 > 5000 B8
L
< 2000
L
< 2000
B8 B8 B8
L L L
< 2000 < 2000 < 2000
B8
L
< 2000
B44 Absent 2.7% spec
tech
MFI
> 5000
B703
L
> 5000
B703
L
B8 > 5000 B8
L L
< 2000 < 2000
B8
L
> 5000
B8
L
2000-5000
B8 B8
F L
< 2000
B8
L
< 2000
L
> 5000
L
B8 > 5000 B8
L L
< 2000 < 2000
L
> 5000
B703
L
> 5000
B703
L
> 5000
> 5000
L
> 5000
L
> 5000
B44
F
B44
L
> 5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 68 73
< 2000 1 2000-5000 0 > 5000 66
38 73
< 2000 27 2000-5000 11 > 5000 0
68 73
< 2000 0 2000-5000 3 > 5000 64
4 73
< 2000 1 2000-5000 0 > 5000 2
1 73
< 2000 1 2000-5000 0 > 5000 0
4 73
< 2000 2 2000-5000 0 > 5000 1
70 73
< 2000 0 2000-5000 0 > 5000 69
12 73
< 2000 0 2000-5000 0 > 5000 12
20 73
< 2000 16 2000-5000 1 > 5000 2
2 73
< 2000 0 2000-5000 0 > 5000 1
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 3 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B45 Conse Absent % rep 1.4% tech MFI Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 B45 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
F
B13 Present 94.5% spec
tech
MFI
B64 Absent 2.7% spec
B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 B64 > 5000 2000-5000 2000-5000 2000-5000 > 5000 B64 > 5000
B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L
2000-5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B13 B13 B13 B13
L L L L
> 5000 > 5000 > 5000 2000-5000
tech
L
MFI
B65 Absent 4.1% spec
MFI
B62 Not Assessed 5.5% spec
tech
MFI
B63 Not Assessed 58.9% spec
tech
MFI
B63 B63 B63 B63 B63 B63 B63
L L L L L L L
< 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000
B63 B63
L L
< 2000 < 2000
B63 B63 B63
L L L
2000-5000 < 2000 < 2000
B63 B63 B63 B63 B63 B63 B63 B63
L L L L L L L L
< 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000
B63 B63 B63 B63 B63
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B63 B63
L L
2000-5000 2000-5000
B63 B63 B63
L L L
< 2000 < 2000 < 2000
B63
L
B63 B63 B63 B63
L L L L
< 2000 < 2000 < 2000 < 2000
B63
L
< 2000
B75 Absent 2.7% spec
tech
MFI
B77 Absent 2.7% spec
tech
MFI
B38 Absent 4.1% spec
tech
MFI
B39 Absent 4.1% spec
tech
< 2000 B65
F
tech
L
2000-5000 B62
L
> 5000
B62
L
> 5000
B65
F
B62
F
B65
L
2000-5000 B62
L
B63 B63 B63
L F L
L L L
L
> 5000 B77
L
> 5000 B38
L
> 5000 B39
L
B39
F
B75
L
> 5000 B77
L
> 5000 B38
L
> 5000
L
tech
MFI
B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000, 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
B57 B57 B57 B57 B57 B57 2000-5000 B57 B57
L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 > 5000 < 2000
B57 B57
F L
2000-5000
B57 B57 B57
L L L
> 5000 2000-5000 2000-5000
B57 B57 B57 B57 B57
L L L L L
< 2000 2000-5000 2000-5000 < 2000 2000-5000
B57
L
< 2000
B57 B57 B57 B57
L L L L
2000-5000 < 2000 2000-5000 < 2000
< 2000
2000-5000 < 2000 < 2000 B38
B63
B57 Present 86.3% spec
< 2000
> 5000
B63 B63 B63
B75
MFI
L
< 2000 B39
L
< 2000
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 0 > 5000 0
69 73
< 2000 0 2000-5000 12 > 5000 57
2 73
< 2000 1 2000-5000 0 > 5000 0
3 73
< 2000 0 2000-5000 2 > 5000 0
4 73
< 2000 0 2000-5000 0 > 5000 3
43 73
< 2000 32 2000-5000 9 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 2
2 73
< 2000 0 2000-5000 0 > 5000 2
3 73
< 2000 1 2000-5000 0 > 5000 2
3 73
< 2000 1 2000-5000 1 > 5000 0
63 73
< 2000 15 2000-5000 44 > 5000 2
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 4 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B58 Conse Present % rep 79.5% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B18 Absent 4.1% spec
tech
MFI
B49 Not Assessed 6.8% spec
tech
MFI
B50 Absent 2.7% spec
tech
MFI
B54 Present 89.0% spec
tech
2000-5000 B55 B55 B55
L F L
2000-5000
> 5000
B54 B54 B54
L L L
> 5000 B55 2000-5000 B55 2000-5000 B55
L L L
2000-5000 B56 > 5000 B56 2000-5000 B56
L L L
B54 B54 B54 B54 B54
L L L L L
< 2000 > 5000 > 5000 2000-5000 2000-5000
< 2000
B54 B54
L L
B55 B55 B55 B55 B55 B55 2000-5000 B55 < 2000 B55
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000
B56 B56 B56 B56 B56 B56 B56 B56
< 2000 < 2000 < 2000 < 2000
B54 B54 B54 B54
L L L L
> 5000 < 2000 > 5000 < 2000
L L L L
> 5000 2000-5000 > 5000 < 2000
B56 B56 B56 B56
< 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000
B58
L
< 2000
B58 B58 B58 B58
L L L L
< 2000 < 2000 < 2000 < 2000
B58 B58 B58 B58
L L L L
< 2000 > 5000 < 2000 > 5000
B58 B58
F L
2000-5000
B58
L
> 5000
B58
L
< 2000
B58
L
< 2000
B58 B58 B58
L L L
2000-5000 < 2000 < 2000
B58
L
B58 B58 B58 B58
L L L L
B18
L
B18
L
B49
L
< 2000
B49
L
< 2000
L L L L L L
2000-5000
F
B18
< 2000
B49
F
B50
F
> 5000
B49
L
< 2000 B50
L
2000-5000
B55 B55 B55 B55
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000
tech
L F L
L L L L L L L L L L L L L L L L L L L L L
L
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
B56 Present 94.5% spec
B54 B54 B54
B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58
B49
B54 B54 B54 B54 B54 B54
MFI
L
< 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000
2000-5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000
tech
B54
L L L L L L L L L L L L L L L
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
B55 Present 93.2% spec
B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 B55 2000-5000 B55 < 2000 B55 > 5000 B55 2000-5000 B55 > 5000 B55 > 5000 B55 B55 2000-5000 B55
B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58
B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54 B54
MFI
> 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000
> 5000
MFI
B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000
B27 Present 93.2% spec B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27
tech L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
MFI > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B2708 Not Assessed 61.6% spec L L
> 5000 > 5000
B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708
L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B2708 B2708
L L
> 5000 > 5000
B2708 B2708 B2708
L L L
> 5000 > 5000 > 5000
B2708
L
> 5000
B2708 B2708 B2708
L L L
> 5000 > 5000 > 5000
L
2000-5000
B27 B27 B27
L F L
2000-5000 B2708
L L L L L L L L
> 5000 B27 > 5000 B27 2000-5000 B27 B27 2000-5000 B27 > 5000 B27 > 5000 B27 > 5000 B27 > 5000 B27 < 2000 B27 > 5000 B27 2000-5000 B27
L L L L L L L L L L L L
> 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L L L L
> 5000 2000-5000 > 5000 < 2000
L L L L
> 5000 > 5000 B2708 > 5000 2000-5000 B2708
B27 B27 B27 B27
MFI
B2708 B2708
B27
> 5000
tech
B35 Not Assessed 5.5% spec
tech
MFI
B35
L
> 5000
B35
L
2000-5000
B35
F
B35
L
L
> 5000
B2708
L
> 5000
B2708
L
> 5000
B2708
L
> 5000
B2708
L
> 5000
L
> 5000
L
> 5000
> 5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 58 73
< 2000 40 2000-5000 14 > 5000 3
3 73
< 2000 0 2000-5000 1 > 5000 1
5 73
< 2000 4 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 0
65 73
< 2000 7 2000-5000 27 > 5000 30
68 73
< 2000 1 2000-5000 14 > 5000 51
69 73
< 2000 2 2000-5000 12 > 5000 54
68 73
< 2000 0 2000-5000 5 > 5000 62
45 73
< 2000 0 2000-5000 0 > 5000 44
4 73
< 2000 0 2000-5000 1 > 5000 2
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 5 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B37 Not Assessed Conse % rep 9.6% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
B37
L
B37
L
B37
L
B37
L
B37
F
B37
L
B37
L
MFI
B60 Present 93.2% spec
< 2000
MFI
B61 Present 90.4% spec
tech
MFI
B41 Not Assessed 43.8% spec
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L L L F L
2000-5000 > 5000 B61 > 5000 B61 B61 > 5000 B61
L L F L
> 5000 2000-5000
B60 B60
L L
> 5000 > 5000
B61 B61
L L
> 5000 > 5000
B60 B60 B60 B60 B60 B60 B60 B60 B60
L L L L L L L L L
> 5000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B61 B61 B61 B61 B61 B61 B61 B61
L L L L L L L L
< 2000 > 5000 > 5000 B41 > 5000 B41 > 5000 > 5000 B41 > 5000 2000-5000
B60 B60 B60 B60
L L L L
> 5000 > 5000 > 5000 2000-5000
B61 B61 B61 B61
L L L L
> 5000 B41 > 5000 > 5000 2000-5000
B60 B60 < 2000 B60 B60 < 2000 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 2000-5000 B60 B60 > 5000 B60 B60 B60 B60 B60 > 5000
tech
> 5000
tech
MFI
B42 Present 91.8% spec
tech
MFI
B42 B42 B42 B42
L L L L
> 5000 > 5000 > 5000 > 5000
B42 B42 B42 B42 < 2000 B42 B42 < 2000 B42 B42 B42 B42 B42 B42 < 2000 B42 B42 B42 < 2000 B42 < 2000 B42 < 2000 B42 B42 < 2000 B42 B42 < 2000 B42 B42 < 2000 B42 2000-5000 B42 < 2000 B42 B42 < 2000 B42 < 2000 B42 B42 < 2000 B42 < 2000 B42 < 2000 B42 B42 B42 B42 B42 < 2000 B42 < 2000 B42 < 2000 B42 B42 > 5000 B42 < 2000 B42 2000-5000 B42 B42 B42 B42 < 2000 B42
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
L L L F L
> 5000 > 5000 > 5000
B41
L
< 2000
B41
L
< 2000
B41
L
< 2000
B41
L
B41
L
B41
L
B41 B41 B41
L L L
B41
L
B41
L
B41 B41 B41
L L L
B41 B41
L L
B41 B41 B41
L L L
B41 B41 B41
L L L
B41 B41 B41
L L L
B46 Absent 4.1% spec
tech
B46
L
B46
F
B46
L
MFI
B47 Present 93.2% spec
tech
MFI
B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47 B47
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000
B47 B47 B47 B47 B47 B47 2000-5000 B47 B47 B47 B47 B47 B47
L L L L L L L L L L F L
< 2000
B47 B47 B47
B48 Present 91.8% spec B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48 B48
tech
MFI
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 B48 B48 > 5000 B48
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 B53
L F L
2000-5000
L L L
> 5000 B48 2000-5000 B48 2000-5000 B48
L L L
> 5000 > 5000 < 2000
B41 B41
F L
B41
L
2000-5000 B42 B42 B42
L L L
> 5000 > 5000 > 5000
L L
< 2000 < 2000
L
> 5000
B42 B42 B42 B42 B42 B42 B42 B42
L L L L L L L L
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B47 B47 B47 B47 B47 B47 B47 B47
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000
B48 B48 B48 B48 B48 B48 B48 B48
L L L L L L L L
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
L
< 2000
B42 B42 B42 B42
L L L L
> 5000 > 5000 > 5000 2000-5000
B47 B47 B47 B47
L L L L
> 5000 > 5000 > 5000 2000-5000
B48 B48 B48 B48
L L L L
> 5000 2000-5000 > 5000 < 2000
> 5000
B53 Absent 2.7% spec
tech
L
B53
F
MFI
B59 Absent 4.1% spec
tech
MFI
2000-5000
B59
F
B59
L
> 5000
B59
L
< 2000
> 5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 7 73
< 2000 3 2000-5000 1 > 5000 2
68 73
< 2000 1 2000-5000 3 > 5000 63
66 73
< 2000 1 2000-5000 4 > 5000 60
32 73
< 2000 26 2000-5000 3 > 5000 2
67 73
< 2000 1 2000-5000 4 > 5000 61
3 73
< 2000 1 2000-5000 1 > 5000 0
68 73
< 2000 0 2000-5000 16 > 5000 51
67 73
< 2000 4 2000-5000 7 > 5000 55
2 73
< 2000 0 2000-5000 1 > 5000 0
3 73
< 2000 1 2000-5000 0 > 5000 1
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 6 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B67 Conse Present % rep 93.2% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B71 Absent 4.1% spec
tech
MFI
B72 Not Assessed 5.5% spec
tech
MFI
B73 Present 93.2% spec
tech
MFI
B78 Absent 4.1% spec
B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 B73 > 5000 B73 B73 > 5000 B73 B73
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 B78 2000-5000
B73 B73 B73
L F L
2000-5000
> 5000 B73 B73 B73
L L L
2000-5000 B78 > 5000 2000-5000
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B73 B73 B73 B73 B73 B73 B73 B73
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000
> 5000 2000-5000 > 5000 2000-5000
B73 B73 B73 B73
L L L L
> 5000 2000-5000 > 5000 2000-5000
B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67 B67
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 B71 > 5000 > 5000 B71 > 5000
B67 B67 B67
L F L
> 5000
B67 B67 B67
L L L
> 5000 > 5000 > 5000
B67 B67 B67 B67 B67 B67 B67 B67
L L L L L L L L
B67 B67 B67 B67
L L L L
B71
L
> 5000
B72
L
L
2000-5000 B72
L
F
B72
F
> 5000 B72
L
tech
L
B78
F
> 5000 L
MFI
B81 Present 91.8% spec
tech
MFI
B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81
L L L L L; L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B81
B82 Present 90.4% spec
tech
MFI
Cw1 Not Assessed 49.3% spec C L L L L
Cw1
L
Cw1 Cw1
L L
Cw1 Cw1
L L
Cw1 Cw1
L L
Cw1 Cw1 Cw1 Cw1
L L L L
Cw1 Cw1 Cw1 Cw1
L L L L
Cw1 Cw1
L L
Cw1
L
Cw1 Cw1
MFI
L
> 5000
B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000
B81 B81 B81
L F L
> 5000 B82
L
2000-5000
> 5000 B82
L
> 5000
Cw1 Cw1
F L
< 2000
2000-5000 B81 B81 B81
L L L
> 5000 B82 > 5000 B82 > 5000 B82
L L L
2000-5000 Cw1 > 5000 2000-5000
L
> 5000
B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81
L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B82 B82 B82 B82 B82
L L L L L
2000-5000 > 5000 > 5000 Cw1 > 5000 > 5000 Cw1
B82 B82
L L
> 5000 2000-5000
B82 B82 B82 B82
L L L L
Cw1 > 5000 Cw1 2000-5000 > 5000 Cw1 < 2000
2000-5000
Cw1 Cw1 Cw1 Cw1 Cw1
tech
Cw2 Present 75.3% spec
< 2000 < 2000 2000-5000 < 2000 < 2000
tech
MFI
Cw2 Cw2 Cw2 Cw2 Cw2 2000-5000 Cw2 Cw2 < 2000 Cw2 < 2000 Cw2 Cw2 2000-5000 Cw2 < 2000 Cw2 Cw2
L L L L L L L L L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000
Cw2 Cw2 Cw2 Cw2 Cw2 2000-5000 Cw2 2000-5000 Cw2 < 2000 Cw2 < 2000 Cw2 Cw2 Cw2 Cw2 < 2000 Cw2 < 2000 Cw2 < 2000 Cw2 < 2000 Cw2
L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 > 5000 2000-5000
2000-5000 Cw2 2000-5000 Cw2 Cw2 < 2000 Cw2 Cw2 Cw2
L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
L
< 2000
Cw2
L
2000-5000
L
< 2000
Cw1 Cw1
L L
< 2000 < 2000
Cw2 Cw2 Cw2 Cw2
L L L L
2000-5000 < 2000 2000-5000 2000-5000
Cw1
L
< 2000
Cw2
L
2000-5000
Cw2
L
< 2000
Cw2 Cw2 Cw2
L F L
< 2000
Cw2 Cw2
L L
L
Cw2 2000-5000 Cw2 Cw2 < 2000 Cw2
L L L L
2000-5000 2000-5000 2000-5000 2000-5000
Cw2
L
< 2000
L L
> 5000 < 2000
L
< 2000
Cw2 Cw2 Cw2
L L L
2000-5000 < 2000 2000-5000
L
< 2000 < 2000
Cw9 Absent 4.1% spec
tech
Cw9
L
Cw9
F
> 5000 Cw9 2000-5000
L
MFI
> 5000
2000-5000 > 5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 68 73
< 2000 0 2000-5000 6 > 5000 61
3 73
< 2000 0 2000-5000 1 > 5000 1
4 73
< 2000 0 2000-5000 0 > 5000 3
68 73
< 2000 0 2000-5000 15 > 5000 52
3 73
< 2000 0 2000-5000 2 > 5000 0
67 73
< 2000 0 2000-5000 0 > 5000 66
66 73
< 2000 1 2000-5000 14 > 5000 51
36 73
< 2000 25 2000-5000 8 > 5000 2
55 73
< 2000 10 2000-5000 41 > 5000 3
3 73
< 2000 0 2000-5000 0 > 5000 2
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 7 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment Cw10 Conse Absent % rep 4.1% tech MFI Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 Cw10 214 216 218 222 Cw10 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 Cw10 303 309 351 361 392
L
Cw4 Absent 1.4% spec
tech
MFI
> 5000 Cw4
L
F
Cw5 Absent 4.1% spec
tech
Cw5
L
Cw5
F
Cw5
L
MFI
Cw6 Absent 1.4% spec
tech
MFI
Cw7 Absent 1.4% spec
MFI
Cw8 Absent 1.4% spec
tech
MFI
Cw12 Absent 1.4% spec
tech
Cw14 Not Assessed 34.2% spec
MFI
tech
MFI
Cw14 Cw14 Cw14
L L L
< 2000 < 2000 < 2000
Cw14
L
< 2000
Cw14
L
2000-5000
Cw14
L
< 2000
Cw14 Cw14 Cw14
L L L
< 2000 < 2000 < 2000
Cw14
L
< 2000
Cw14 Cw14 Cw14
L L L
< 2000
Cw14 Cw14
L L
2000-5000 < 2000
Cw14
L
< 2000
Cw14
L
< 2000
Cw14 Cw14
L L
< 2000 < 2000
Cw14
L
< 2000
Cw15 Not Assessed 6.8% spec
tech
Cw16 Absent 4.1% spec
MFI
Cw15
L
< 2000
Cw15
L
< 2000
tech
MFI
Cw17 Not Assessed 5.5% spec
tech
MFI
Cw18 Absent 4.1% spec
tech
Cw17
L
< 2000
Cw17
L
> 5000 Cw18
L
MFI
< 2000
> 5000
Cw15
L
> 5000 Cw16
L
> 5000
Cw15
F
Cw16
F
Cw17
F
Cw18
F
Cw15
L
> 5000 Cw16
L
2000-5000 Cw17
L
> 5000 Cw18
L
> 5000
< 2000 Cw6
F
Cw8
F
Cw12
F
Cw14 Cw14
F L
< 2000
> 5000
Cw7 L
tech
L
Cw14
L
< 2000
Cw14
L
< 2000
Cw14
L
< 2000
> 5000
< 2000
> 5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 3 73
< 2000 0 2000-5000 0 > 5000 2
1 73
< 2000 1 2000-5000 0 > 5000 0
3 73
< 2000 0 2000-5000 0 > 5000 2
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
25 73
< 2000 21 2000-5000 2 > 5000 0
5 73
< 2000 2 2000-5000 0 > 5000 2
3 73
< 2000 0 2000-5000 1 > 5000 1
4 73
< 2000 1 2000-5000 0 > 5000 2
3 73
< 2000 0 2000-5000 0 > 5000 2
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 8 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018 DESPATCHED ON 17 APRIL 2018 Techniques used IgG
Sample Treatment IgG
High Background
9 11 12 14
L L L L
EDTA NO EDTA NO EDTA EDTA, Heat NO Inactivation
15 19 20 23 24 25 26 28 34 35 38 39 41 42 45
L L C, L L L L L L L L L L L L L
Neg control serum batch
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 500 1500
8800 3702 9374 11922
81 101 114 23
LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1251 500 1424/982 1000
11707 9410 12098 9675 7761 10056 10852 10443 12007 12117 10301 9733 7706 12155 12000
35 66 100 21 57 53 73 28 20 15 25 23 15 178 40
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LSA1SA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
1100 1000 1000 >1500 541 500 1000 1000 500 1000 500
10749 7984 10730 13906 13032 15295 5652 5795 8770 7887 7916 12546
36 95 59 54 202 179 25 55 29 23 21 83
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1000
13900 7690 14559 9453 21466 7202.6 6680
70 45 318 29 305 46.86 14.4
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 35 1000 500 2 1000 1000
9399 5460 8655 9094 16343 10464 9236
38 154 63 28 149 33 91
LS1A04 LM1 A*01:01/03:01/11:01/11:02/2 LSA1SA 4:02/24:03/25:01/29:01/29:0 2/30:01/31:01/32:01/34:02/3 6:01/66:02/74:01/80:01 B*07:02/07:03/13:02/27:03/2 7:05/27:08/40:01/40:02/42:0 1/47:01/54:01/55:01/56:01/5 7:01/58:01/67:01/73:01/81:0 1/82:02 C*02:02
1000 1000 750
14407 20123 10021
23 70 120
LM1 LSAI&IISA
3000 1000
19671 15650
681 212
LM1 LS1A04 LSA1SA
1000 1200
>10000 7291 18527
37 12 93
LM1 LSA1SA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
2 500 2000 1500 500 1000 500 500
21242 13287 11381 11858 7980 8729 11684 7984 11874
330 168 13 27 25 18.94 137 20.7
LS1A04
1000
8095
130
LSA1SA LS1A04 LSA1SA
550 1500 500
13954 8875 14599
106 65 118
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LSM12
5.5
3403
273
LSM12 LSM12 LSM12
4.5 7.1 3.6
9402 12625 11900
475 133.62 94
16256
87
750
12741
127
6228
124
LSM12
1.5
9415
29
LSM12
3
7767
53
LM1
2
18649
563
LS1PRA
2000
7036
93
LSM12
2.5
10586
46
Luminex kit (lot)
Cut-off value
Control bead MFI Negative
Cut-off value
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LS1PRA LSA1SA
1000 1500
9311 11828
454 84
LSA1SA
1500
11446
60
LMX
1
18963
81
Lab no.
48 L 51 54 58 62 100 112 114 116 117 119 120 133
L L L L L L L L L L L L
136 142 143 145 149 157 160
C, L L L L L L L
162 165 169 181 185 194 195 197 206 212 214
L L L L L C, L L L C, L L L
EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA, Adsorption beads Heat Inactivation EDTA EDTA EDTA
EDTA EDTA EDTA EDTA EDTA
EDTA
EDTA Adsorption Beads EDTA
EDTA EDTA EDTA
229 230 L 232 L 242 L 252 267 268 273 277 284 292 293 294 302 303
L L C, L L L L L L L L L
309 L 351 L 361 L 392
NO NO NO NO NO NO NO
18 18 In House 19 18 19 19
NO NO NO NO NO NO NO
18 19 18 18 18 19
NO
19
NO NO NO NO NO NO NO NO NO NO NO NO
A*34:02 A*34:02
18 18 17 3005724
NO NO NO NO NO NO NO
15
NO NO NO NO NO NO NO
18
18 17
A*34:02 A*01:01, A*03:01, A*11:01, A*11:02, A*24:02, A*24:03, A*25:01, A*29:02, A*30:01, A*31:01, A*32:01, A*36:01, A*66:02, A*74:01, A*80:01, B*07:01/02/03, B*13:02, B*27:03/05/08, B*40:01, B*40:02, B*42:01, B*47:01, B*48:01, B*54:01, B*55:01, B*56:01, B*57:01, B*58:01, B*67:01, B*73:01, B*81:01, B82:02
A*34:02 A*34:02
A*66:02, A*66:01
NO
3005464 NO
EDTA, Dilution
A*01:01, A*03:01, A*11:01, A*11:02, A*23:01 A*24:02, A*24:03, A*25:01, A29:01, A*29:02, A*30:01, A*32:01, A*33:03, A*36:01, A*66:01, B*07:02 B*07:03, B*13:02, B*27:03, B*27:05, B*40:01, B*40:02, B*42:01, B*47:01, B*48:01, B*54:01, B*55:01, B*56:01, B*57:01, B*58:01, B*67:01, B*73:01, B*81:01, B82:02, B*15:16/B63, C*02:02, C*04:01
3006081 18
Adsorption Beads
EDTA EDTA EDTA
B*40:01, B*40:02 NO NO NO NO NO NO NO NO
EDTA, Heat NO Inactivation
EDTA
LSA1SA
LSA1SA
LSM12
NO NO NO
EDTA EDTA
1380 2000 500 1500
A*34:02
18 18 19 3006187 3005724
YES
216 L 218 L
222 F 227 L
18 18 18
NO NO NO
A*34:02, A*66:02 19 18
A*34:01 A*66:02, A*33:01
18
NEQ‐119 A*66:02 18 3006015
A*66:02
Issue 2
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 9 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A1 Present 97.3% spec tech
Consensus % reported Lab no. 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1
L L L L L L C, L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1
L L L L L L L L L L L L L L L L L
A2 Absent 1.4% spec
tech
MFI
A23 Present 95.9% spec
tech
MFI
A24 Present 95.9% spec
tech
MFI
A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L L L F L
> 5000 > 5000 > 5000 > 5000
A24 A24 A24 A24 A24
L L L F L
> 5000 2000-5000 > 5000
> 5000
A23 A23 A23 A23 A23
> 5000
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 A2 > 5000 > 5000 > 5000 > 5000
A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23 A23
L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000
A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24 A24
L L L L L L L L L L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000
A2403 Absent 1.4% spec
A2403
tech
L
MFI
A25 Present 83.6% spec
tech
MFI
A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 < 2000 A25 A25 A25 A25 A25 A25 A25
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000
A25 A25 A25 A25 A25 A25 A25 A25
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000
A25 A25 A25 A25 A25
L L L L L
2000-5000 2000-5000 < 2000 2000-5000 < 2000
A25
L
2000-5000
A25
L
A25
A26 Not Assessed 19.2% spec
2000-5000
MFI
L
< 2000
A26
L
< 2000
tech
MFI
A11 Present 76.7% spec
tech
MFI
A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000
A11
L
< 2000
A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000
A11 A11 A11 A11 A11
L L L L L
< 2000 < 2000 2000-5000 2000-5000 < 2000
A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L L L L
2000-5000 2000-5000 > 5000 < 2000 < 2000 2000-5000 < 2000 < 2000 2000-5000 > 5000 < 2000
A11 A11
L L
2000-5000 < 2000
< 2000
A11 A11 A11
L L L
< 2000 2000-5000 < 2000
L
< 2000
A11 A11
F L
< 2000
A25 A25
L L
2000-5000 < 2000
A11
L
2000-5000
A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25 A25
L L L L L L L L L L L L
< 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000
A11 A11 A11 A11 A11 A11
L L L L L L
2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000
A11 A11 A11
L L L
2000-5000 < 2000 2000-5000
A26
L
< 2000
A26
L
< 2000
A26
L
< 2000
A26
L
< 2000
A26 A26
L L
< 2000 < 2000
A26
L
< 2000
A26 A26
L L
< 2000 < 2000
A26
L
tech
A26
A66 Absent 4.1% spec
L
2000-5000
A26
L
< 2000
A26
L
< 2000
A66
L
< 2000
A66
L
2000-5000
A66
L
> 5000
A29 Not Assessed 9.6% spec
tech
MFI
A29
L
< 2000
A29
L
< 2000
A29
L
< 2000
A29
L
< 2000
A29
L
< 2000
A29
L
< 2000
A29
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other Number Total number
71 73
< 2000 0 2000-5000 0 > 5000 70
1 73
< 2000 0 2000-5000 1 > 5000 0
70 73
< 2000 0 2000-5000 3 > 5000 66
70 73
< 2000 0 2000-5000 5 > 5000 64
1 73
< 2000 1 2000-5000 0 > 5000 0
61 73
< 2000 24 2000-5000 37 > 5000 0
14 73
< 2000 13 2000-5000 1 > 5000 0
3 73
< 2000 1 2000-5000 1 > 5000 1
56 73
< 2000 28 2000-5000 25 > 5000 2
7 73
< 2000 7 2000-5000 0 > 5000 0
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 10 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A30 Conse Absent % rep 1.4% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 A30 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A33 Absent 2.7% spec
A33
tech
L
MFI
A68 Absent 2.7% spec
tech
MFI
A69 Absent 4.1% spec
< 2000
A69
L
A69
L
A69 L
tech
L
MFI
A36 Present 90.4% spec
tech
MFI
A43 Present 86.3% spec
tech
MFI
A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43 A43
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000
A43
L
> 5000
A43
L
A43
L
A80 Present 93.2% spec
tech
MFI
2000-5000
A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
> 5000
A80 A80
F L
> 5000
A80 A80 A80
L L L
2000-5000 > 5000 2000-5000
A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80 A80
L L L L L L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000
A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 A36 > 5000 A36 A36 > 5000
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
A36 A36
F L
> 5000
> 5000 A36 A36 A36
L L L
< 2000 2000-5000 2000-5000
A43 A43
L L
> 5000 2000-5000
A36 A36 A36 A36 A36 A36 A36 A36
L L L L L L L L
< 2000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000
A43 A43 A43 A43 A43 A43 A43 A43
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
A36 A36 A36 A36
L L L L
> 5000 < 2000 > 5000 < 2000
A43 A43 A43 A43
L L L L
> 5000 2000-5000 > 5000 < 2000
B52 Absent 2.7% spec
tech
MFI
B7 Absent 1.4% spec
tech
MFI
B8 Present 90.4% spec B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8
B52
L
B52
L
> 5000 B7
L
tech
MFI
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000
C, L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 < 2000
B8 B8 B8
L F L
< 2000
B8 B8
L L
2000-5000 < 2000
B8 B8 B8 B8 B8 B8 B8 B8
L L L L L L L L
< 2000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 < 2000
B8 B8 B8 B8
L L L L
> 5000 < 2000 > 5000 < 2000
B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 B8 > 5000 B8 B8
> 5000
> 5000
2000-5000
A33
L
A68 < 2000 A68
L L
< 2000 < 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 2 2000-5000 0 > 5000 0
2 73
< 2000 2 2000-5000 0 > 5000 0
3 73
< 2000 0 2000-5000 0 > 5000 3
66 73
< 2000 8 2000-5000 32 > 5000 25
63 73
< 2000 3 2000-5000 8 > 5000 52
68 73
< 2000 0 2000-5000 13 > 5000 54
2 73
< 2000 0 2000-5000 0 > 5000 2
1 73
< 2000 0 2000-5000 0 > 5000 1
66 73
< 2000 11 2000-5000 22 > 5000 32
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 11 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B44 Conse Present % rep 82.2% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B45 Present 82.2% spec
tech
MFI
B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000
B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 < 2000 > 5000 < 2000
B44 B44 B44 B44 B44 B44 B44 B44
L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000, 2000-5000 < 2000 2000-5000 < 2000 < 2000
B45 B45 B45 B45 B45 B45 B45 B45
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000
B44 B44 B44 B44 B44
L L L L L
2000-5000 < 2000 < 2000 2000-5000 < 2000
B45 B45 B45 B45 B45
L L L L L
> 5000 < 2000 < 2000 2000-5000 < 2000
B44 B44 B44
L L L
< 2000 2000-5000 < 2000
B45 B45 B45
L L L
2000-5000 > 5000 < 2000
B44 B44
F L
< 2000
B45
L
2000-5000
B44 B44
L L
2000-5000 < 2000
B45 B45
L L
2000-5000 < 2000
B44 B44 B44 B44 B44 B44
L L L L L L
2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000
B45 B45 B45 B45 B45 B45 B45
L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000
B44 B44 B44
L L L
2000-5000 < 2000 < 2000
B45 B45 B45
L L L
2000-5000 < 2000 2000-5000
B13 Absent 1.4% spec
tech
MFI
B64 Absent 2.7% spec
B64
B13
tech
MFI
L
> 5000
B65 Absent 1.4% spec
B65
tech
L
F
MFI
2000-5000
B63 Absent 2.7% spec
B63
L
B63 B64
L
tech
MFI
B75 Absent 2.7% spec
> 5000 B75
tech
L
MFI
B76 Present 84.9% spec
tech
B77 Absent 4.1% spec
MFI
B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76 B76
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B76 B76 B76 B76
L L L L
> 5000 > 5000 > 5000 > 5000
B76
L
> 5000
B76
L
> 5000
2000-5000 B76
L
> 5000
B76
L
> 5000
B76
L
> 5000
B76 B76 B76 B76 B76 B76 B76 B76
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B76 B76 B76 B76
L L L L
> 5000 > 5000 > 5000 2000-5000
tech
MFI
B38 Absent 2.7% spec
tech
MFI
B77
L
> 5000
B77
L
> 5000 B38
L
2000-5000
B77
L
> 5000 B38
L
2000-5000
F
2000-5000
B75
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 60 73
< 2000 30 2000-5000 28 > 5000 0
60 73
< 2000 20 2000-5000 37 > 5000 3
1 73
< 2000 0 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 1
1 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 1
2 73
< 2000 1 2000-5000 1 > 5000 0
62 73
< 2000 0 2000-5000 2 > 5000 60
3 73
< 2000 0 2000-5000 0 > 5000 3
2 73
< 2000 0 2000-5000 2 > 5000 0
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 12 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B39 Conse Absent % rep 1.4% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 B39 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L
MFI
B58 Absent 2.7% spec
> 5000 B58
tech
L
MFI
B18 Absent 1.4% spec
L
MFI
tech
MFI
B50 Absent 1.4% spec
tech
MFI
B54 Absent 2.7% spec
tech
MFI
2000-5000
B55 Absent 1.4% spec
B55
B18
B58
tech
B49 Absent 1.4% spec
F
B49
F
B50
F
B54
F
B54
L
tech
L
MFI
B56 Absent 1.4% spec
tech
MFI
2000-5000
B27 Absent 1.4% spec
B27
tech
L
B37 Absent 4.1% spec
MFI
tech
MFI
B37
L
< 2000
B37
L
< 2000
B37
F
2000-5000
< 2000
2000-5000
B56
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 0 > 5000 1
2 73
< 2000 0 2000-5000 2 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 1 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 1 > 5000 0
3 73
< 2000 2 2000-5000 0 > 5000 0
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 13 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B41 Conse Absent % rep 1.4% Lab n spec tech MFI 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 B41 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
B42 Absent 1.4% spec
tech
B46 Not Assessed 5.5% MFI spec
B46
F
B42
F
tech
L
B46
MFI
B47 Absent 2.7% spec
tech
MFI
B48 Absent 2.7% spec
tech
MFI
B53 Absent 1.4% spec
tech
< 2000
B47
L
> 5000
B48
L
> 5000
B47
L
2000-5000
B48
L
2000-5000
F
B53
B46
L
< 2000
B46
L
< 2000
F
B59 Not Assessed 24.7% MFI spec
tech
MFI
B59
L
< 2000
B59
L
< 2000
B59
L
< 2000
B59
L
< 2000
B59
L
< 2000
B59
L
< 2000
B59 B59
L L
< 2000 < 2000
B59 B59
L L
< 2000 < 2000
B59 B59
L L
< 2000 < 2000
B59
F
B59
L
2000-5000
B59
L
< 2000
B59
L
< 2000
B59 B59
L L
< 2000 < 2000
B67 Absent 2.7% spec
tech
MFI
B67
L
> 5000
B67
L
2000-5000
B71 Absent 1.4% spec
B71
tech
MFI
B73 Absent 2.7% spec
tech
MFI
B73
L
> 5000
B73
L
> 5000
F
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
4 73
< 2000 3 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 1
2 73
< 2000 0 2000-5000 1 > 5000 1
1 73
< 2000 0 2000-5000 0 > 5000 0
18 73
< 2000 16 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 1
1 73
< 2000 0 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 2
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 14 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B78 Conse Absent % rep 1.4% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 B78 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L
MFI
2000-5000
B81 Absent 2.7% spec
B81
tech
L
B81
L
MFI
B82 Present 86.3% spec
tech
MFI
B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82 B82
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
B82 B82 B82 B82 B82 B82 B82 B82
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000
B82 B82 B82 B82 B82
L L L L L
> 5000 2000-5000 < 2000 2000-5000 < 2000
B82 > 5000 B82 B82
L L L
2000-5000 > 5000 < 2000
B82
L
< 2000
B82
L
2000-5000
> 5000 B82 B82 B82
L L L
2000-5000 2000-5000 < 2000
B82 B82 B82 B82 B82 B82 B82 B82
L L L L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000
B82 B82 B82
L L L
2000-5000 < 2000 2000-5000
Cw2 Absent 2.7% spec
Cw2
tech
MFI
L
Cw9 Absent 2.7% spec
tech
MFI
< 2000
Cw4 Absent 1.4% spec
Cw4
Cw9
L
Cw9
F
tech
L
MFI
Cw5 Absent 1.4% spec
tech
MFI
Cw8 Absent 1.4% spec
L
MFI
tech
MFI
Cw14 Absent 1.4% spec
tech
MFI
Cw16 Absent 1.4% spec
tech
MFI
< 2000
2000-5000
Cw12
Cw5
L
> 5000
F
Cw16
Cw14
Cw8 Cw2
tech
Cw12 Absent 2.7% spec
L
2000-5000
Cw12
L
L
F
Cw17 Not Assessed 61.6% spec
tech
MFI
Cw17 Cw17 Cw17 Cw17 Cw17 Cw17 Cw17
L L L L L L L
2000-5000 <2000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
Cw17 Cw17 Cw17 Cw17 Cw17 Cw17
L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
Cw17
L
2000-5000
Cw17 Cw17 Cw17 Cw17 Cw17 Cw17 Cw17 Cw17
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
Cw17 Cw17 Cw17 Cw17 Cw17
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
Cw17 Cw17 Cw17 Cw17
L L L L
2000-5000 2000-5000 2000-5000 < 2000
Cw17
L
< 2000
Cw17 Cw17 Cw17
L L L
2000-5000 2000-5000 < 2000
Cw17 Cw17
L L
< 2000 < 2000
Cw17
L
2000-5000
Cw17 Cw17
F L
< 2000
Cw17
L
2000-5000
Cw17
L
< 2000
Cw17
L
< 2000
Cw17
L
2000-5000
Cw17
L
2000-5000
2000-5000
2000-5000
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 2
63 73
< 2000 17 2000-5000 44 > 5000 2
2 73
< 2000 2 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 1
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 1 > 5000 0
45 73
< 2000 15 2000-5000 28 > 5000 0
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 15 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2018 DESPATCHED ON 17 APRIL 2018 Techniques used IgG
Sample Treatment IgG
High Background
9 11 12 14
L L L L
EDTA NO EDTA NO EDTA EDTA, Heat NO Inactivation
15 19 20 23 24 25 26 28 34 35 38 39 41 42 45
L L L L L L L L L L L L L L L
48 51 54 58 62 100 112 114 116
L L L L L L L L L
Neg control serum batch
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
A*24:02 A*24:02 A*24:02 A*24:02
LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 500 1500
9000 3403 10447 13051
113 273 162 63
LSM12
2.5
4577
367
A*24:02 A*24:02
LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1313 500 1284/674 1000 1040 2000 500 1500
10680 11487 10982 11273 12574 11079 12433 9736 12437 14556 10745 10765 10191 13257 13000
59 49 62 57 181 112 90 47 27 29 21 41 50 364 90
LSM12 LSM12 LSM12
4.5 7.1 3.6
11491 14124 14161
813 206 451
LSA1SA
16486
113
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LSA1SA LS1A04 LS1A04
2500 1000 1000 >1500 493 500 1000 1000
8594 9394 11176 15461 12847 15585 6331 8469
94 112 74 139 252 231 64 79
A*24:02 A*24:02
LS1A04 LS1A04
500 1000
LSM12
7516
537
9493 15929
66 53
A*24:02 A*01:01, A*23:01, A*24:02, A*36:01, A*43:01, A*80:01, B*15:12
LS1A04 LSA1SA
LSM12
1.5
14055
175
500
9109 12912
53 118
A*24:02
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1000
16754 13646 16720 10773 18544 8534.8 11560
116 147 349 29 342 64.48 44
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 67 1000 500 2 1000 1000
11998 6337 8228 10818 16000 11107 10754
125 94 131 77 144 78 43
LSM12
3
7949
289
LM1
2
19949
547
A*24:02 LS1A04 LM1 A*01:01/11:01/11:02/23:01/24 LSA1SA :02/24:03/25:01/36:01/43:01/8 0:01, B*08:01/15:12/44:03/45:01/82 :02 LM1 A*01:01, A*23:01, A*24:02, LSA I&II A*36:01, A*43:01, A*80:01, B*08:01, B*15:12/B76, B*82:02
1000 1500 750
13804 16918 12098
69
3000 1000
18763 15650
349 212
LM1 LS1A04 LSA1SA
1000 1200
>10000 9935 17306
37 41 152
LM1 LSA1SA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04
2 500 2000 1500 500 1000 500
21087 13282 9982 12456 8686 9404 12579
193 270 32 47 49 32.73 93
LS1PRA
2000
8745
433
LSM12
2.5
13720
301
LS1A04 LSA1SA
500
8367 12742
37.4
LS1A04
1000
9698
143
LSA1SA LS1A04 LSA1SA
490 1500 500
13600 10851 14359
143 104 114
Luminex kit (lot)
Cut-off value
Control bead MFI Negative
Cut-off value
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LS1PRA LSA1SA
1000 1500
9752 12427
1111 91
LSA1SA
1500
11044
95
LMX
1
19522
114
Lab no.
117 L 119 L
120 L 133 L
136 142 143 145 149 157 160
C, L L L L L L L
162 165 169 181 185 194 195 197 206 212 214
L L L L L C, L L L L L L
EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA, Adsorption Beads EDTA EDTA EDTA EDTA
EDTA EDTA, Adsorption Beads
NO NO NO NO NO NO NO NO NO NO NO NO NO NO
EDTA Adsorption Beads EDTA
EDTA EDTA
EDTA
229 230 L 232 L 242 L 252 267 268 273 277 284 292
L L C, L L L L L
293 294 302 303
L L L L
309 L 351 L 361 L 392
19
A*24:02
NO YES
18 17
A*24:02
3005724
15
NO NO NO NO NO NO NO
18
18 17
A*24:02
NO
NO
B*15:12
NO NO NO NO NO
19
A*11:02, A*24:02 A*24:02 A*24:02
18
A*24:02
4
NO NO EDTA, Heat NO Inactivation
EDTA
NO NO NO
240
A*24:02
3006081 18
Adsorption Beads
EDTA EDTA EDTA, Adsorption Beads
A*24:02 A*24:02 A*24:02
A*24:02
3005464
EDTA EDTA
A*24:02 A*24:02 A*24:02, A*33:01
18
NO NO NO NO NO NO NO
NO NO
A*24:02 A*24:02 A*24:02
YES
EDTA, Dilution
A*24:02, A*29:02
18 19 18 18 18 19
18 18 19 3006187 3005724
216 L 218
222 F 227 L
4 In House 19 18 19 19
NO NO NO NO NO NO NO NO YES
EDTA. Adsorption Beads EDTA NO Heat NO Inactivation
EDTA
18 18 18
18
A*24:02, A*33:01
18 3006015
NEQ‐119 Issue 2
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 16 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A34 Consensus Not Assessed 52.1% % reported Lab no. spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A34 A34 A34 A34 A34 A34 A34
L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000
A34 A34 A34 A34 A34
L L L L L
2000-5000 2000-5000 < 2000 2000-5000 2000-5000
A34
L
< 2000
A34 A34
L L
2000-5000 < 2000
A34 A34 A34 A34
L L L L
2000-5000 < 2000 2000-5000 2000-5000
A34 A34
L L
< 2000 < 2000
A34 A34 A34 A34
L L L L
2000-5000 2000-5000 2000-5000 < 2000
A34 A34
L L
2000-5000 < 2000
A66 Present 94.5% spec A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66
tech
MFI
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L C, L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000, > 5000 2000-5000 < 2000 2000-5000 > 5000 > 5000 2000-5000,> 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000
A34 A34
L L
< 2000 2000-5000
A34
L
2000-5000 A66 A66 A66 A66 A66
L L L L L
> 5000 < 2000 < 2000 < 2000 < 2000
A34
L
< 2000
A66
L
2000-5000
A66 < 2000 A66 A66 A66 A66 A66 2000-5000 A66 < 2000 A66 2000-5000 A66 < 2000 A66 < 2000 A66 A66 A66 < 2000 A66 A66 A66 A66
L L L L L L L L L L L L L L L L L
< 2000 2000-5000 < 2000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000
A33 Absent 1.4% spec
A33
tech
L
MFI
A69 Absent 1.4% spec
< 2000
L
A34 A34 A34 A34 A34
L L L L L
A34
L
MFI
B7 Present 79.5% spec
tech
MFI
B703 Absent 2.7% spec
tech
MFI
B13 Present 78.1% spec
tech
MFI
B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7 B7
L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 2000-5000
B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
B7 B7 B7 B7 B7
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B13 B13 B13 B13 B13
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B7 B7 B7 B7 B7 B7 B7 B7
L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000
B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L
< 2000 2000-5000 > 5000 < 2000, 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
B7 B7 B7 B7 B7 B7 B7
L L L L L L L
> 5000 < 2000 < 2000 B703 2000-5000 < 2000 2000-5000 < 2000
B13 B13 < 2000 B13 B13 B13 B13 B13
L L L L L L L
> 5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000
B7 B7
F L
< 2000
B13 B13
F L
< 2000
B13
L
< 2000
B7
L
< 2000
B7
L
< 2000
B7 B7 B7 B7 B7 B7 B7 B7 B7 B7
L L L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000 B703 < 2000
B13 B13 B13 B13 B13 B13 B13 B13 < 2000 B13 B13
L L L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 < 2000
B64 Absent 1.4% spec
F
L
L
tech
MFI
B38 Absent 1.4% spec
B38
B64
A69
A34
tech
L
tech
L
MFI
B39 Absent 4.1% spec
tech
MFI
< 2000 B39
L
< 2000
B39
L
< 2000
B39
L
< 2000
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other Number Total number
38 73
< 2000 18 2000-5000 20 > 5000 0
69 73
< 2000 14 2000-5000 27 > 5000 28
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
58 73
< 2000 33 2000-5000 22 > 5000 2
2 73
< 2000 2 2000-5000 0 > 5000 0
57 73
< 2000 30 2000-5000 23 > 5000 2
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
3 73
< 2000 3 2000-5000 0 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 17 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B3901 Conse Absent % rep 1.4% tech MFI Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 B3901 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L
B58 Absent 1.4% spec
tech
< 2000
MFI
B49 Absent 4.1% spec
B49
tech
L
MFI
B50 Not Assessed 13.7% spec
MFI
B50
L
< 2000
B50
L
< 2000
B50
L
< 2000
B50
L
< 2000
< 2000 B50
L
< 2000
B50
L
< 2000
B50 B58
tech
L
B54 Absent 1.4% spec
tech
2000-5000
C
B50
B49
L
B49
L
< 2000 B50
L
2000-5000
B54
L
tech
MFI
B55 B55 B55
L L L
< 2000 < 2000 < 2000
B55
L
< 2000
B55 B55 B55
L L L
< 2000 < 2000 < 2000
B55 B55 B55 B55
L L L L
< 2000 < 2000 < 2000 < 2000
B55
L
< 2000
B55 B55 B55 B55
L L L L
< 2000 < 2000 < 2000 < 2000
B55 B55 B55 B55
L L L L
< 2000 < 2000 < 2000 < 2000
B55 B55 B55 B55 B55 B55
L L L L L L
< 2000 < 2000 2000-5000 < 2000 < 2000 < 2000
B55 B55
L L
2000-5000 < 2000
B55 B55
L L
< 2000 < 2000
B56 Absent 1.4% spec
B56
tech
L
< 2000
F
B50
B55 Not Assessed 52.1% spec
MFI
F
B55 B55
F L
B55 B55 B55 B55 B55
< 2000
L L L L L
B55
L
< 2000
< 2000 < 2000 < 2000 < 2000 < 2000 < 2000
MFI
B27 Present 89.0% spec
tech
MFI
B2708 Not Assessed 63.0% spec
tech
MFI
B37 Absent 2.7% spec
B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 < 2000 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27 B27
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 > 5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 < 2000 < 2000 2000-5000 2000-5000 > 5000 < 2000
B2708 B2708
L L
2000-5000 B37 2000-5000
B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708 B2708
L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000
B2708 B2708
L L
< 2000 2000-5000
B2708 B2708
L L
2000-5000 2000-5000
B2708
L
2000-5000
B2708 B2708 B2708
L L L
2000-5000 < 2000 2000-5000
B2708
L
< 2000
B27 B27 B27
L F L
< 2000
B2708
L
< 2000
2000-5000
B27 B27
L L
< 2000 < 2000
B2708
L
< 2000
B27 B27 B27 B27 B27 B27 B27 B27
L L L L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
B2708
L
< 2000
B2708
L
2000-5000
B2708
L
2000-5000
B2708
L
< 2000
B27 B27 B27 B27
L L L L
2000-5000 < 2000 B2708 2000-5000 < 2000 B2708
L
< 2000
L
< 2000
B37
tech
MFI
L
< 2000
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
3 73
< 2000 2 2000-5000 0 > 5000 0
10 73
< 2000 8 2000-5000 2 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
38 73
< 2000 35 2000-5000 2 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
65 73
< 2000 18 2000-5000 41 > 5000 5
46 73
< 2000 14 2000-5000 29 > 5000 3
2 73
< 2000 2 2000-5000 0 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 18 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B60 Conse Present % rep 80.8% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B61 Present 79.5% spec
tech
MFI
B41 Not Assessed 69.9% spec
tech
MFI
B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60
L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61
L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000, 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B41 B41 B41 B41 B41 B41
L L L L L L
< 2000 2000-5000 < 2000 < 2000 < 2000 < 2000
B41 B41 B41
L L L
B41 B41 B41 B41 B41 B41 B41
L L L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000
B41 B41 B41 B41 B41
L L L L L
< 2000 2000-5000 2000-5000 < 2000 2000-5000
B60 B60 B60 B60 B60 B60
L L L L L L
< 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
B61 B61 B61 B61 B61
L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000
B41 B41 B41 B41 B41
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B60 B60 B60 B60 B60 B60 B60 B60
L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 > 5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000
L L L L L L L L
L L L L L L L
L L L L L L L L L L L L L L L L
B41 B41 B41 B41 B41 B41 B41 B41
B60 B60 B60 B60 B60 B60 B60
B61 B61 B61 B61 B61 B61 B61 B61 B61 > 5000 B61 < 2000 B61 < 2000 B61 2000-5000 B61 2000-5000 B61 2000-5000 B61 < 2000 B61
B41 B41 B41 B41 B41 B41 B41
B60 B60
F L
< 2000
B61 B61
F L
< 2000
B60
L
< 2000
B61
L
< 2000
B60 B60 B60 B60 B60 B60 B60 B60 B60 B60 B60
L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000
B61 B61 B61 B61 B61 B61 B61
L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000
B61 B61 B61
L L L
2000-5000 < 2000 2000-5000
B42 Not Assessed 54.8% spec
tech
MFI
B46 Absent 1.4% spec
tech
MFI
B47 Not Assessed 17.8% spec
B42 B42 B42
L L L
< 2000 < 2000 < 2000
B47
B42
L
2000-5000 B42 < 2000 B42 < 2000 B42
L L L
B42 B42 B42 B42
L L L L
< 2000 < 2000 < 2000 2000-5000
B47
L
B47
B42
L
< 2000
B42 B42 B42 B42
L L L L
< 2000 < 2000 < 2000 2000-5000
B42 B42 B42 B42
L L L L
< 2000 < 2000 2000-5000 < 2000
2000-5000 < 2000 > 5000 < 2000 < 2000 < 2000 < 2000 < 2000
B42 B42 B42 B42 B42 B42
L L L L L L
< 2000 < 2000 2000-5000 < 2000 < 2000 < 2000
B42
L
< 2000
L L L L L L L
> 5000 < 2000 < 2000 2000-5000 < 2000 < 2000 < 2000
B42 B42
L L
> 5000 < 2000
B41 B41
F L
< 2000
B41 B41 B41 B41 B41 B41
L L L L L L
B41 B41
L L
tech
tech
MFI
B59 Absent 2.7% spec
tech
MFI
B67 Not Assessed 68.5% spec
tech
MFI
L L L
< 2000 < 2000 < 2000
B67 B67 B67
L L L
2000-5000 2000-5000 < 2000
< 2000
B48 B48
L L
< 2000 < 2000
B67 B67
L L
< 2000 < 2000
< 2000 < 2000 < 2000
B48 B48 B48
L L L
< 2000 < 2000 < 2000
B67 B67 B67
L L L
2000-5000 < 2000 < 2000
< 2000
B48 B48
L L
< 2000 < 2000
L
< 2000
B48
L
2000-5000
B67 B67 B67 B67 B67
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B47
L
< 2000
B48
L
< 2000
B67
L
< 2000
B47
L
< 2000
B48 B48 B48 B48
L L L L
2000-5000 < 2000 < 2000 < 2000
B67 B67 B67 B67 B67
L L L L L
< 2000 2000-5000 2000-5000 < 2000 2000-5000
B47
L
< 2000
B48 B48 B48 B48 B48
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
B67 B67 B67 B67 B67
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B48
L
< 2000
B47
L
< 2000
B48 B48 B48 B48
L L L L
2000-5000 < 2000 < 2000 < 2000
B67 B67 B67 B67 B67 B67 B67 B67
L L L L L L L L
2000-5000 2000-5000 > 5000 < 2000 < 2000 < 2000 < 2000 < 2000
< 2000 B47
L
2000-5000 B59 < 2000
L
L
2000-5000 B48 B48 < 2000 B48
L L
B47
L
< 2000
B47
L
< 2000
B48 B48
L L
< 2000 < 2000
< 2000 B67 B67 B67 B67 B67 B67 B67
L L L L L L L
> 5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000
F
B67 B67
F L
< 2000
L
< 2000
B48 Not Assessed 52.1% spec B48 B48 B48
B46
L
MFI
B42 B42 B42
L L L
< 2000 < 2000 < 2000
B42 B42
F L
< 2000
B48
L
< 2000
2000-5000 < 2000 2000-5000 2000-5000 < 2000 < 2000
B42 B42 B42 B42 B42
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
B48 B48 B48 B48 B48
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
B67 B67 B67 B67 B67 B67
L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 < 2000
< 2000 < 2000
B42
B48
L
< 2000
B67 B67 B67
L L L
< 2000 < 2000 < 2000
L
B59
B47
L
< 2000
B47
L
< 2000
B47
L
< 2000
< 2000
B71 Absent 1.4% spec
B71
tech
MFI
F
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 59 73
< 2000 19 2000-5000 37 > 5000 2
58 73
< 2000 18 2000-5000 36 > 5000 2
51 73
< 2000 35 2000-5000 13 > 5000 2
40 73
< 2000 34 2000-5000 4 > 5000 1
1 73
< 2000 1 2000-5000 0 > 5000 0
13 73
< 2000 12 2000-5000 1 > 5000 0
38 73
< 2000 34 2000-5000 4 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 0
50 73
< 2000 32 2000-5000 15 > 5000 2
1 73
< 2000 0 2000-5000 0 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 19 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B73 Not Assessed Conse % rep 17.8% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B81 B81 B81 B81 B81 B81
L L L L L L
< 2000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
B81 B81 2000-5000 B81 B81 B81 B81 B81 B81
L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000
2000-5000 B81 B81 B81 < 2000 B81 B81
L L L L L
> 5000 < 2000 < 2000 2000-5000 2000-5000
B81
L
< 2000
B81 B81
F L
< 2000
B81
L
< 2000
B81 B81 B81 B81 B81 B81 B81 B81 B81 B81
L L L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 < 2000 < 2000 B82 2000-5000 < 2000 < 2000
B73
L
< 2000
B73
L
< 2000
B73
L
< 2000
B73
L
< 2000
B73
L
< 2000
L
B73
L
B73
L
B73 B73 B73
L L L
B82 Absent 1.4% spec
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
< 2000
B73
MFI
L L L L L L L L L L L L L L L L L L L L L L L L
L
L
tech
B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81 B81
B73
B73
B81 Present 78.1% spec
< 2000
< 2000 < 2000 < 2000
tech
MFI
Cw1 Absent 1.4% spec
tech
MFI
Cw9 Absent 1.4% spec
tech
MFI
Cw7 Absent 1.4% spec
Cw7
L
< 2000 Cw1
L
< 2000 Cw9
L
tech
L
< 2000
MFI
Cw17 Absent 2.7% spec
tech
MFI
< 2000
Cw17
F
Cw17
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 13 73
< 2000 11 2000-5000 2 > 5000 0
57 73
< 2000 24 2000-5000 30 > 5000 2
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 20 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2018 DESPATCHED ON 17 APRIL 2018 Techniques used IgG
Sample High Neg control Treatment Background serum IgG batch
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
L L L L
EDTA EDTA NO EDTA EDTA, No Heat inactivation
18 18 18
B*13:02 B*13:02, A*34:01
LS1A04 LS1A04 LS1A04 LS1A04
1500 1000 500 1500
9800 4657 11763 15300
69 438 541 86
NO NO YES
18 4 In House
A*34:01, B*13:02 A*34:01 A*34:01, B*13:02
LS1A04 LS1A04 LS1A04
1000 1000 1000
11633.08 11933 13429
243.68 103 174
NO YES NO YES
19 18 19
NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO YES NO YES
18 19 18 18 18 19
LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 1000 1219 500 954/692 1000 1090 2000 500 1500
10501 13723 10568 141.36 11866 11971 13094 14717 10407 8609 14797 15000
77 172 204 84 190 120 65 53 104 57 351 180
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LSA1SA LS1A04 LS1A04 LS1A04 LS1A04
400 1000 1000 >1500 779 500 1000 1000 500 1000
9022 9988 11904 21173 12737 16622 6417 11393 10719 17996
254 169 36 203 119 200 49 105 174 78
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LSM12
2.5
7307
292
LSM12 LSM12 LSM12
4.5 7.1 3.6
13758 16513 17878
1429 395 1436
16167
92
12701
92
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LS1PRA LSA1SA
1000 1500
12985 12471
1900 87
LMX
1
19230
91
Luminex kit (lot) Cut-off value Control bead Control bead MFI MFI IgG Positive Negative
IgG
Lab no. 9 11 12 14
15 L 19 L 20 C, L 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119
L L L L L L L L L L L L L L L L L L L L L L L
120 L 133 L 136 142 143 145 149 157 160
C, L L L L L L L
162 165 169 181 185 194 195 197 206 212 214 216 218
L L L L L L L L C, L L L F L
222 F 227 L 229 230 L 232 L 242 L 252 267 268 273 277 284 292 293 294 302 303
L L C, L L L L L L L L L
309 L 351 L 361 L 392
EDTA EDTA, Adsorption Beads EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA
EDTA EDTA
EDTA, Adsorption Beads EDTA NO EDTA NO
NO EDTA NO NO NO NO EDTA NO Adsorption NO Beads EDTA NO NO NO NO EDTA NO EDTA NO EDTA
18 18 17
A*34:01 A*34:01
A*34:01 B*07:002
500
9349 12912
86 118
1000 1000 1000 1000 1000 1000 1000
21549 9898 27058 12084 23130 9790.8 9413
195 144 352 62 316 82.81 17.8
1000 61 1000 500 2 1000 1000
11683 8740 19114 10305 15839 11842 11292
109 141 309 39 117 145 83
1000 1000 750 3000 1000
11375 18330 12798 17473 14164
101 95 118 92 120
LM1 LS1A04 LSA1SA
1000 1200
>10000 8301 17952
37 55 87
18
B*27:08 A*34:01 A*34:01 A*34:01 A*34:01
LM1 LSA1SA LS1PRA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
2 500 2000 1500 500 1000 500 500
20713 13236 7856 14356 8068 9095 9845 10860 12183
112 174 235 122 50 99.89 97 26.3
18
B*13:02, A*34:01
LS1A04
1000
8959
148
27:05
LSA1SA LS1A04 LSA1SA
750 1500 500
13041 11665 15262
171 169 137
3005724
15 18 17
LS1A04 A*66:01, A*66:02, B*27:05, LSA1SA B*27:08 A*34:01 LS1A04 LS1A04 LS1A04 A*34:01 LS1A04 LSA1SA B13:02 LS1A04 LS1A04 B*13:02 A*34:01
18
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
A*34:01
NO
LS1A04 LM1 LSA1SA LM1 A*66:01, A*66:02, B*27:05, LSA I&II SA B*27:08 A*66:02, B*27:08
LSA1SA
1500
15275
71
LSA1SA
750
LSM12
8722
574
LSM12
1.5
15566
220
LSM12
3
8352
207
LM1
2
18362
97
LS1A04
2000
9703
58
LSM12
2.5
13192
194
NO NO NO
3006081 18 B*40:01
Adsorption Beads NO NO NO NO NO NO NO NO
EDTA, NO Heat inactivation EDTA
A*33:01, A*34:01
A*34:01
NO
EDTA EDTA EDTA
A*34:01, B*13:02
18 18 19 3006187 3005724
3005464
EDTA EDTA
A*34:01 B*13:02
LSA1SA
19
YES
EDTA, Dilution
A*34:01, B*13:02 B*13:02
NO NO NO
18 19
18 3006015
B*27:05
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 21 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A2 Absent 1.4% spec tech
Consensus % reported Lab no. 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A3 Absent 2.7% spec
tech
MFI
A23 Not Assessed 5.5% spec
A23
tech
L
A24 Not Assessed 12.3% MFI spec
< 2000 A24
tech
L
A2403 Not Assessed 9.6% MFI spec
L
< 2000
A2403
L
< 2000 A25
L
< 2000
L L
< 2000 < 2000
L
< 2000 A24
L
< 2000 A2403
A23
L
< 2000 A24
L
< 2000
A24 A24
L L
< 2000 A2403 < 2000 A2403
L
MFI
< 2000 A2403
A23
A23
tech
A25 Absent 2.7% spec
tech
MFI
A26 Absent 2.7% spec
L
> 5000 A26
L
< 2000
L
A26
L
2000-5000
A3
L
2000-5000
A3
L
2000-5000
tech
MFI
> 5000 A34
L
> 5000
A34
L
2000-5000
A34
L
< 2000
A34
F
A34
L
2000-5000
A34
L
2000-5000
A66 Absent 1.4% spec
A66
tech
L
A11 Not Assessed 5.5% MFI spec
tech
MFI
> 5000 A11
L
> 5000
A11
L
2000-5000
A11
F
A11
L
< 2000
A25
A2
tech
A34 Not Assessed 8.2% MFI spec
A24 A24
L L
< 2000 < 2000
A24
L
< 2000 A2403
L
< 2000
A24
L
< 2000 A2403
L
< 2000
F
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other Number Total number
1 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 2 > 5000 0
4 73
< 2000 4 2000-5000 0 > 5000 0
9 73
< 2000 9 2000-5000 0 > 5000 0
7 73
< 2000 7 2000-5000 0 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 1
2 73
< 2000 0 2000-5000 0 > 5000 1
6 73
< 2000 1 2000-5000 3 > 5000 1
1 73
< 2000 0 2000-5000 0 > 5000 1
4 73
< 2000 1 2000-5000 1 > 5000 1
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 22 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A29 Conse Absent % rep 2.7% Lab n spec tech 9 11 12 14 15 19 20 23 24 A29 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 A29 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L
L
MFI
> 5000
2000-5000
A30 Absent 2.7% spec
A30
tech
L
A30
L
MFI
> 5000
2000-5000
A31 Absent 2.7% spec
A31
tech
L
A31
L
MFI
A32 Present 89.0% spec
tech
MFI
A32 A32 A32 A32 A32 A32 A32 A32
L L L L L L L L
> 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000
A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 < 2000 < 2000 2000-5000 2000-5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 > 5000 2000-5000 > 5000 > 5000
A32
L
< 2000
A32 A32
F L
> 5000
2000-5000
2000-5000
A33 Not Assessed 5.5% spec
A33
L
A33
L
A33
A32 A32 A32 A32 A32 A32 A32 A32 A32 A32 A32
L L L L L L L L L L L
2000-5000 < 2000 2000-5000 < 2000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 < 2000
A32 A32 A32 A32
L L L L
>5000 2000-5000 2000-5000 < 2000
tech
MFI
L
tech
MFI
> 5000
> 5000
F
A33
A74 Absent 4.1% spec
A74
L
A74
F
A74
L
A68 Not Assessed 5.5% spec
tech
MFI
A68
L
< 2000
A68
L
> 5000
A68
L
< 2000
A68
L
2000-5000
A69 Absent 1.4% spec
A69
tech
L
MFI
2000-5000
A36 Absent 1.4% spec
A36
tech
L
MFI
A43 Absent 1.4% spec
< 2000 A43
tech
L
MFI
> 5000
< 2000
2000-5000
2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 2 73
< 2000 0 2000-5000 1 > 5000 1
2 73
< 2000 0 2000-5000 1 > 5000 1
2 73
< 2000 0 2000-5000 2 > 5000 0
65 73
< 2000 10 2000-5000 26 > 5000 27
4 73
< 2000 0 2000-5000 1 > 5000 2
3 73
< 2000 1 2000-5000 1 > 5000 0
4 73
< 2000 2 2000-5000 1 > 5000 1
1 73
< 2000 0 2000-5000 1 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 1
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 23 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B51 Conse Present % rep 89.0% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B5102 Not Assessed 45.2% spec
tech
MFI
B51 B51 B51 B51 B51 B51 B51 B51
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B5102 B5102 B5102 B5102
L L L L
> 5000 > 5000 > 5000 > 5000
B5102 B5102
L L
> 5000 > 5000
B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51 B51
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
B5102 B5102 B5102 B5102
L L L L
> 5000 > 5000 > 5000 > 5000
B5102 B5102 B5102 B5102 B5102 B5102 B5102 B5102
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B5102 B5102 B5102 B5102
L L L L
> 5000 > 5000 > 5000 > 5000
B5102 B5102
L L
> 5000 > 5000
B5102
L
> 5000
B5102
L
> 5000
B5102
L
> 5000
B5102 B5102
L L
> 5000 > 5000
B51
L
< 2000
B51 B51 B51
L F L
2000-5000
B51 B51
L L
> 5000 2000-5000
B51 B51 B51 B51 B51 B51 B51 B51
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B51 B51 B51 B51
L L L L
>5000 2000-5000 > 5000 < 2000
B5103 Absent 1.4% spec
tech
> 5000 B5102
L
> 5000
B5102 B5102
L L
> 5000 B5103 > 5000
B5102
L
> 5000
L
MFI
B52 Present 91.8% spec
tech
MFI
B44 Present 86.3% spec
tech
MFI
B45 Present 87.7% spec
tech
MFI
B52 B52 B52 B52 B52 B52 B52 B52
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B44 B44 B44 B44 B44 B44 B44 B44
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000
B45 B45 B45 B45 B45 B45 B45 B45
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52 B52
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000
B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44 B44
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 < 2000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 > 5000 2000-5000 > 5000 > 5000
B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45
L L L L L L L L L L L L L L L L L L L L L L
B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45 B45
B52 B52 B52
L F L
> 5000
B44
L
< 2000
> 5000
B44
L
B52 B52 B52
L L L
2000-5000 > 5000 > 5000
B44 B44
B52 B52 > 5000 B52 B52 B52 B52 B52 B52
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B52 B52 B52 B52
L L L L
>5000 2000-5000 > 5000 2000-5000
B13 Present 86.3% spec
tech
MFI
2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000
B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 < 2000 > 5000 2000-5000 < 2000, 2000-5000 > 5000 < 2000, 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 > 5000 < 2000 < 2000 2000-5000 > 5000 > 5000 2000-5000, > 5000 > 5000
L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 < 2000 2000-5000 < 2000 > 5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 2000-5000,> 5000 < 2000 > 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 < 2000 > 5000 > 5000 2000-5000 > 5000 2000-5000
L F L
< 2000 2000-5000
B13 B13 B13
L F L
< 2000
> 5000
B45 B45 B45
L L
2000-5000 < 2000
B45 B45 B45
L L L
2000-5000 2000-5000 < 2000
B13 B13
L L
2000-5000 < 2000
B44 B44 B44 B44 B44 B44 B44 B44
L L L L L L L L
< 2000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 < 2000
B45 B45 B45 B45 B45 B45 B45 B45
L L L L L L L L
< 2000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
B13 B13 B13 B13 B13 B13 B13
L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000
B44 B44 B44 B44
L L L L
>5000 < 2000 > 5000 < 2000
B45 B45 B45
L L L
2000-5000 < 2000 2000-5000
B13 B13 B13
L L L
2000-5000 < 2000 > 5000
B64 Absent 2.7% spec
B64
tech
L
MFI
2000-5000
> 5000 B64
L
2000-5000
B62 Present 89.0% spec
tech
MFI
B62 B62 B62 B62 B62 B62 B62 B62
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62 B62
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
B62 B62 B62 B62 B62 B62 B62 B62
L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000
B62 B62 B62
L F L
2000-5000
B62 B62
B63 Present 91.8% spec
tech
MFI
B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000
B63
L
2000-5000
> 5000
B63 B63 B63
L F L
> 5000
L L
2000-5000 > 5000
B63 B63
L L
2000-5000 > 5000
B62 B62 B62 B62 B62 B62 B62 B62
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B62 B62 B62 B62
L L L L
>5000 2000-5000 > 5000 < 2000
B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63 B63
L L L L L L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 >5000 2000-5000 > 5000 2000-5000
2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 65 73
< 2000 3 2000-5000 9 > 5000 51
33 73
< 2000 0 2000-5000 0 > 5000 33
1 73
< 2000 0 2000-5000 0 > 5000 1
67 73
< 2000 2 2000-5000 10 > 5000 53
63 73
< 2000 11 2000-5000 20 > 5000 31
64 73
< 2000 13 2000-5000 43 > 5000 7
63 73
< 2000 9 2000-5000 17 > 5000 34
2 73
< 2000 0 2000-5000 2 > 5000 0
65 73
< 2000 3 2000-5000 12 > 5000 48
67 73
< 2000 1 2000-5000 14 > 5000 50
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 24 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B75 Conse Present % rep 89.0% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B75 B75 B75 B75 B75 B75 B75 B75
L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000
B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75 B75
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 2000-5000 > 5000 2000-5000, > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 < 2000
B75 B75 B75
L F L
< 2000
B75 B75
L L
< 2000 2000-5000
B75 B75 B75 B75 B75 B75 B75 B75
L L L L L L L L
< 2000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000
B75 B75 B75 B75
L L L L
2000-5000 < 2000 2000-5000 < 2000
> 5000
B76 Not Assessed 45.2% spec
tech
MFI
B76 B76
L L
< 2000 < 2000
B76 B76
L L
< 2000 < 2000
B76
L
< 2000
B76
L
< 2000
B76
L
< 2000
B76 B76 B76
L L L
< 2000 < 2000 < 2000
B76 B76 B76 B76 B76
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B76 B76 B76 B76
L L L L
< 2000 < 2000 2000-5000 < 2000
B76
L
< 2000
B76
L
2000-5000
B76 B76 B76 B76
L L L L
2000-5000 < 2000 < 2000 < 2000
B76
L
< 2000
B76
L
< 2000
B76 B76 B76 B76
L L L L
< 2000 < 2000 < 2000 < 2000
B76 B76
L L
<2000 < 2000
B77 Present 86.3% spec
tech
MFI
B38 Present 86.3% spec
tech
MFI
B57 Present 89.0% spec
tech
MFI
B58 Present 87.7% spec
tech
MFI
B18 Absent 1.4% spec
tech
MFI
B49 Present 93.2% spec
tech
MFI
B50 Present 90.4% spec
tech
MFI
B77 B77 B77 B77 B77 B77 B77 B77
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000
B38 B38 B38 B38 B38 B38 B38 B38
L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000
B57 B57 B57 B57 B57 B57 B57 B57
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B58 B58 B58 B58 B58 B58 B58 B58
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B49 B49 B49 B49 B49 B49 B49 B49
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B50 B50 B50 B50 B50 B50 B50 B50
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77 B77
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000
B77 B77 B77
L L L
> 5000 < 2000 < 2000
B38
L
> 5000
B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 < 2000 > 5000 > 5000 2000-5000 > 5000
B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58 B58
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 < 2000 > 5000 > 5000 2000-5000 > 5000
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
> 5000 2000-5000 > 5000 > 5000
> 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 < 2000 2000-5000 > 5000 < 2000 > 5000 > 5000
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
L L L L
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49
B77 B77 B77 B77
B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38 B38
B57
L
< 2000
B58
L
< 2000
B49 B49 B49 B49 B49 B49 B49 B49 B49
L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000
B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50 B50
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000
B77
L
2000-5000
B57
L
2000-5000
B58
L
< 2000
L
> 5000
L F L
< 2000
B77
B38 B38 B38
> 5000
B57
L
> 5000
B58
L
> 5000
B49 B49
F L
> 5000
B50 B50
F L
> 5000
B77 B77
L L
< 2000 2000-5000
2000-5000 > 5000 > 5000
B50 B50 B50 B50 B50 B50 B50 B50
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B77 B77 B77 B77
L L L L
> 5000 > 5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 >5000 2000-5000 > 5000 2000-5000
L L L
L L L L L L L L
L L L L L L L L L L L L L L L L L
B50 B50 B50
B77 B77 B77 B77 B77 B77 B77 B77
B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49 B49
B50 B50 B50 B50
L L L L
>5000 2000-5000 > 5000 2000-5000
B38 B38
L L
2000-5000 < 2000
B57 B57
L L
2000-5000 2000-5000
B58 B58
L L
> 5000 2000-5000
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
B38 B38 B38 B38 B38 B38 B38 B38
L L L L L L L L
< 2000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 < 2000
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
L L L L
2000-5000 < 2000 > 5000 < 2000
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000 >5000 < 2000 > 5000 < 2000
L L L L L L L L
B38 B38 B38 B38
L L L L L L L L L L L L L
B58 B58 B58 B58 B58 B58 B58 B58
>5000 < 2000 > 5000 < 2000
B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57 B57
B58 B58 B58 B58
L L L L
>5000 < 2000 > 5000 < 2000
B18
L
> 5000
B54 Not Assessed 5.5% spec
tech
MFI
B54
L
< 2000
B54
L
< 2000
B54
L
< 2000
B54
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 65 73
< 2000 12 2000-5000 35 > 5000 17
33 73
< 2000 28 2000-5000 4 > 5000 0
63 73
< 2000 9 2000-5000 10 > 5000 43
63 73
< 2000 12 2000-5000 17 > 5000 33
65 73
< 2000 10 2000-5000 12 > 5000 42
64 73
< 2000 11 2000-5000 7 > 5000 45
1 73
< 2000 0 2000-5000 0 > 5000 1
68 73
< 2000 0 2000-5000 7 > 5000 58
66 73
< 2000 0 2000-5000 11 > 5000 53
4 73
< 2000 4 2000-5000 0 > 5000 0
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 25 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B55 Conse Not Assessed % rep 20.5% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
B55
L
MFI
MFI
tech
MFI
tech
MFI
tech
MFI
L L L L L L L L
< 2000 < 2000 2000-5000 < 2000 < 2000 < 2000 < 2000 < 2000
B60 B60 B60 B60 B60 B60 B60 B60
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000
B61 B61 B61 B61 B61 B61 B61 B61
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000
B41 B41 B41 B41 B41 B41 B41 B41
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56 B56
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000
< 2000 < 2000 2000-5000 < 2000 < 2000 < 2000
B60 B60 B60 B60 B60 B60 B60
L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000
B37 B37 B37 B37 B37 B37 B37
L L L L L L L
< 2000 2000-5000 < 2000 < 2000 2000-5000 < 2000 < 2000
B60 B60 B60 B60 B60 B60 B60
L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61 B61
L L L L L L L L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41
L L L L L L L L L L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000
B37 B37 B37 B37 B37
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
B60 B60 B60 B60 B60
L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000
B61 B61 B61 B61 B61
L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B41 B41 B41 B41 B41
L L L L L
B37
L
< 2000
B37 B37
L L
2000-5000 < 2000
B60 B60 B60 B60 B60 B60
L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000
B61 B61 B61 B61 B61 B61
L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
> 5000 2000-5000 < 2000
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 2000-5000 > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
L L L L L L
L L L
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
B37 B37 B37 B37 B37 B37
< 2000 B56 B56 B56
B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35
L
< 2000
B56 < 2000 B56
F L
> 5000
B35 B35 B35
L F L
> 5000
B56 B56 B56
L L L
2000-5000 2000-5000 2000-5000
B56 B56 B56 < 2000 B56 B56 < 2000 B56 B56 B56
L L L L L L L L
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
B56 B56 B56 B56
L L L L
>5000 < 2000 > 5000 < 2000
< 2000 < 2000 < 2000
B55 B55 B55
L L L
< 2000 < 2000 < 2000
B55
L
< 2000
B55
L
< 2000
B55
L
< 2000
L
tech
B37 B37 B37 B37 B37 B37 B37 B37
L L
B55
MFI
B41 Present 76.7% spec
2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000
L
L
tech
B61 Not Assessed 74.0% spec
L L L L L L L L
B55 B55
B55
MFI
B60 Not Assessed 72.6% spec
B35 B35 B35 B35 B35 B35 B35 B35
B55
L
tech
B37 Not Assessed 58.9% spec
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
< 2000
B55
MFI
B35 Present 90.4% spec
L L L L L L L L
L
L
tech
B27 Absent 1.4% spec
B56 B56 < 2000 B56 B56 B56 B56 B56 B56
B55
B55
B56 Present 89.0% spec
B27
F
B35 B35
L L
2000-5000 2000-5000
B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35 B35
L L L L L L L L L L L L L
< 2000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000
tech
B46 Not Assessed 57.5% MFI spec
tech
MFI
B46 B46 B46 B46
L L L L
< 2000 < 2000 < 2000 < 2000
B46 B46
L L
< 2000 2000-5000
B46
L
< 2000
B46 B46
L L
< 2000 < 2000
B46
L
2000-5000
B46 B46 B46 B46 B46
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B46 B46 B46 B46 B46
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 < 2000 > 5000 2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
B46 B46 B46 B46
L L L L
< 2000 < 2000 2000-5000 < 2000
B37
L
< 2000
B37
L
2000-5000
B60 B60
L L
2000-5000 < 2000
B61 B61
L L
B37
L
< 2000
B60
L
2000-5000
B61
L
2000-5000
B37 B37
L L
< 2000 < 2000
B60 B60
L L
2000-5000 2000-5000
B61 B61
L L
2000-5000 2000-5000
B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41 B41
B37
L
2000-5000
B60 B60
L L
2000-5000 < 2000
B61 B61
L L
2000-5000 < 2000
B41 B41
L L
2000-5000 < 2000
L F L
L
< 2000
2000-5000
B61 B61 B61
B41
< 2000
L F L
< 2000
L
B60 B60 B60
< 2000
B37
2000-5000
B41
L
2000-5000
B60 B60
L L
< 2000 < 2000
B61 B61
L L
2000-5000 2000-5000
B41 B41
L L
2000-5000 2000-5000
B41 B41 B41 B41 B41 B41
L L L L L L
< 2000
B42 Absent 1.4% spec
B42
F
B46
L
< 2000
B46
L
2000-5000
B46 B46 B46 B46 B46
L L L L L
> 5000 < 2000 < 2000 < 2000 < 2000
B46 B46
L L
< 2000 < 2000
B46 B46
F L
< 2000
B46
L
< 2000
2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000
B46 B46 B46 B46
L L L L
2000-5000 < 2000 < 2000 2000-5000
B37
L
< 2000
B37 B37 B37 B37
L L L L
2000-5000 < 2000 < 2000 2000-5000
B60 B60 B60 B60 B60 B60
L L L L L L
2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000
B61 B61 B61 B61 B61 B61
L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
B37
L
2000-5000
B60
L
2000-5000
B61
L
2000-5000
B41
L
2000-5000
B46
L
<2000
B37
L
< 2000
B60
L
2000-5000
B61
L
2000-5000
B41
L
2000-5000
B46
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 15 73
< 2000 15 2000-5000 0 > 5000 0
65 73
< 2000 7 2000-5000 11 > 5000 45
1 73
< 2000 0 2000-5000 0 > 5000 0
66 73
< 2000 12 2000-5000 37 > 5000 16
43 73
< 2000 32 2000-5000 11 > 5000 0
53 73
< 2000 16 2000-5000 36 > 5000 0
54 73
< 2000 7 2000-5000 45 > 5000 1
56 73
< 2000 6 2000-5000 43 > 5000 7
1 73
< 2000 0 2000-5000 0 > 5000 0
42 73
< 2000 32 2000-5000 7 > 5000 1
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 26 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B47 Conse Not Assessed % rep 67.1% Lab n spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B47 B47 B47 B47 B47 B47 B47 B47
L L L L L L L L
< 2000 < 2000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 < 2000
B47
L
2000-5000
B47 B47 B47 B47
L L L L
2000-5000 < 2000 < 2000 < 2000
B47 B47 B47 B47 B47 B47 B47
L L L L L L L
< 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
B47 B47 B47 B47 B47
L L L L L
< 2000 < 2000 < 2000 < 2000 < 2000
B47 B47 B47 B47 B47 B47
L L L L L L
2000-5000 < 2000 2000-5000 2000-5000 2000-5000 < 2000
B47
L
2000-5000
B47 B47 B47 B47
L L L L
2000-5000 < 2000 2000-5000 < 2000
B47 B47
L L
2000-5000 < 2000
B47 B47 B47
L F L
< 2000
B47 B47
L L
2000-5000 < 2000
B47 B47 B47 B47
L L L L
2000-5000 < 2000 2000-5000 < 2000
B47
L
<2000
B47
L
< 2000
B48 Absent 4.1% spec
tech
B48
L
B48
L
MFI
L
tech
MFI
B59 Present 89.0% spec
tech
MFI
B71 Present 90.4% spec
tech
MFI
B72 Present 90.4% spec
tech
MFI
B73 Absent 1.4% spec
tech
MFI
B78 Present 82.2% spec
tech
MFI
B53 B53 < 2000 B53 B53 B53 B53 B53 B53
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B59 B59 B59 B59 B59 B59 B59 B59
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B71 B71 B71 B71 B71 B71 B71 B71
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B72 B72 B72 B72 B72 B72 B72 B72
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
B78 B78 B78 B78 B78 B78 B78 B78
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
B53 B53 < 2000 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53 B53
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000
B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59 B59
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72 B72
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 < 2000
2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000
B78 B78
L L
2000-5000 2000-5000
B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78
L L L L L L L L L L L
2000-5000 < 2000 2000-5000 < 2000 > 5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 2000-5000
B78
L
2000-5000
< 2000
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000
L L L L L L L L L L L L L L L L L L L L L L
L
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78 B78
B59
B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71 B71
B53 B53 B53
L F L
2000-5000
B59 B59 B59
L F L
L F L
B72 B72 B72
L F L
2000-5000
> 5000
B71 B71 B71
< 2000
> 5000
< 2000 B53 B53 B53
L L L
2000-5000 > 5000 2000-5000
L L
> 5000 2000-5000
B71 B71
L L
2000-5000
B59 B59
B72 B72
L L
2000-5000 2000-5000
B53 B53 B53 B53 B53 B53 B53 B53
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
B59 B59 B59 B59 B59 B59 B59 B59
L L L L L L L L
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
B71 B71 B71 B71 B71 B71 B71 B71
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
B72 B72 B72 B72 B72 B72 B72 B72
L L L L L L L L
B53 B53 B53 B53
L L L L
>5000 < 2000 > 5000 < 2000
B59 B59 B59 B59
L L L L
>5000 < 2000 > 5000 < 2000
B71 B71 B71 B71
L L L L
>5000 < 2000 > 5000 < 2000
B72 B72 B72 B72
L L L L
2000-5000 B48
B53 Present 91.8% spec
2000-5000
> 5000
B78 B78 B78
L F L
2000-5000
B78 B78
L L
< 2000 < 2000
< 2000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000
B78 B78 B78 B78 B78 B78 B78 B78
L L L L L L L L
< 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
>5000 < 2000 > 5000 < 2000
B78 B78 B78
L L L
2000-5000 < 2000 2000-5000
B73
F
> 5000
B81 Absent 2.7% spec
tech
MFI
B82 Absent 2.7% spec
tech
MFI
B81
L
< 2000 B82
L
2000-5000
B81
L
< 2000 B82
L
> 5000
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 49 73
< 2000 25 2000-5000 22 > 5000 0
3 73
< 2000 3 2000-5000 0 > 5000 0
67 73
< 2000 5 2000-5000 14 > 5000 46
65 73
< 2000 7 2000-5000 7 > 5000 49
66 73
< 2000 7 2000-5000 10 > 5000 46
66 73
< 2000 8 2000-5000 9 > 5000 47
1 73
< 2000 0 2000-5000 0 > 5000 0
60 73
< 2000 15 2000-5000 42 > 5000 2
2 73
< 2000 2 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 1
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 27 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment Cw1 Conse Absent % rep 1.4% Lab n spec tech 9 11 12 14 15 19 20 23 24 Cw1 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
Cw9 Not Assessed 31.5% MFI spec
Cw9
L
tech
L
MFI
Cw10 Not Assessed 41.1% spec
< 2000
Cw10 Cw10
tech
L L
MFI
Cw4 Absent 1.4% spec
tech
< 2000 < 2000
Cw5 Not Assessed 35.6% MFI spec
tech
MFI
Cw5
L
< 2000
Cw5 Cw5 Cw5
L L L
< 2000 < 2000 2000-5000
Cw5 Cw5 Cw5 Cw5 Cw5
L L L L L
< 2000 < 2000 < 2000 2000-5000 < 2000
Cw9
L
< 2000
Cw10 Cw10
L L
< 2000 2000-5000
Cw9
L
< 2000
Cw10
L
< 2000
Cw9
L
< 2000
Cw10
L
< 2000
Cw5
L
2000-5000
Cw9
L
< 2000
Cw10
L
< 2000
Cw5 Cw5
L L
2000-5000 2000-5000
Cw9 Cw9
L L
< 2000 < 2000
Cw10 Cw10
L L
< 2000 < 2000
Cw5 Cw5 Cw5 Cw5
L L L L
2000-5000 < 2000 < 2000 < 2000
Cw9 Cw9 Cw9
L L L
< 2000 < 2000 < 2000
Cw10 Cw10 Cw10 Cw10
L L L L
< 2000 < 2000 < 2000, 2000-5000 < 2000
Cw5
L
< 2000
Cw9
L
< 2000
< 2000 < 2000 2000-5000 < 2000
< 2000 2000-5000
< 2000 < 2000
L L L L
L L
L L
Cw10 Cw10 Cw10 Cw10
Cw5 Cw5
Cw9 Cw9
Cw10
L
< 2000
Cw9
L
2000-5000
Cw10
L
2000-5000 Cw5
L
< 2000
Cw9
L
< 2000
Cw10
L
< 2000
Cw5
L
< 2000
Cw9
L
< 2000
Cw10 Cw10
L L
< 2000 < 2000
Cw5
L
< 2000
Cw9
L
< 2000
Cw10
L
< 2000
Cw5
L
< 2000
Cw6 Absent 1.4% spec
tech
Cw8 Not Assessed 5.5% MFI spec
Cw8
tech
L
MFI
Cw12 Absent 4.1% spec
Cw9 Cw9 Cw9 Cw9
L L L L
Cw4 < 2000
< 2000 < 2000 < 2000 < 2000
Cw10
L
Cw10 Cw10 Cw10 Cw10
L L L L
< 2000 < 2000 < 2000 2000-5000
Cw10 Cw10
L L
2000-5000 <2000
Cw8 Cw8
L L
< 2000 < 2000
Cw8
L
< 2000
F
Cw12
< 2000
Cw5
L
tech
MFI
tech
MFI
Cw17 Absent 2.7% spec
Cw17
Cw12
F L
MFI
Cw16 Absent 2.7% spec
< 2000
< 2000
Cw9 Cw9
tech
Cw14 Absent 4.1% spec
L
tech
L
MFI
Cw18 Absent 4.1% spec
tech
MFI
< 2000 Cw18
L
< 2000
Cw18
L
< 2000
Cw18
L
2000-5000
< 2000
F
Cw14
L
Cw14
F
Cw14
L
2000-5000
Cw16
F
Cw17
F
< 2000
Cw5
L
< 2000
Cw5
L
< 2000
Cw6
L
< 2000
Cw12
L
< 2000
2000-5000
Cw16
L
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 1 2000-5000 0 > 5000 0
23 73
< 2000 21 2000-5000 1 > 5000 0
30 73
< 2000 23 2000-5000 5 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
26 73
< 2000 19 2000-5000 7 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
4 73
< 2000 4 2000-5000 0 > 5000 0
3 73
< 2000 2 2000-5000 0 > 5000 0
3 73
< 2000 0 2000-5000 2 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 0
3 73
< 2000 2 2000-5000 1 > 5000 0
NEQ‐119 Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 28 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/201 DESPATCHED ON 17 APRIL 2018 Techniques used IgG
Sample Treatment IgG
High Background
9 11 12 14
L L L L
EDTA NO EDTA EDTA, NO Heat Inactivation
15 19 20 23 24 25 26 28 34 35 38 39 41 42 45
L L C, L L L L L L L L L L L L L
EDTA
Neg control serum batch
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LS1A04 LS1A04 LS1A04 LS1A04
1500 1000 500 1500
9800 4971 9275 13036
69 65 72 20
LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1483 500 1352/983 1000 1300 2000 500 1500
11063 13322 11832 11858 10941 10391 11198 10210 12674 12245 10126 10007 9969 12448 12000
55 32 56 31 75 62 23 46 22 12 19 26 30 113 20
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LSA1SA
800 1000 1000 >1500 568 500
11829 9299 11895 14997 12719 16519
31 52 30 93 115 196
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
1000 500 1000 500
8327 11072 12038 10148 11762
60 25 30 17 93
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1000
16915 10927 16250 12061 20859 8782.2 6818
66 34 139 399 380 31.79 12
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 132 1000 500 2 1000 1000
16621 6061 1493 10305 16549 11875 8750
80 45 13 39 142 26 30
LS1A04 LM1 LSA1SA
1000 1000 750
14410 20778 11892
13 79 151
3000 750
20281 17438
107 298
LM1 LS1A04 LSA1SA
1000 1200
>10000 8039 17557
37 18 133
LSA1SA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
500 2000 1500 500 1000 500 500
12397 12204 13315 9361 9577 10540 18.6 12813
150 16 34 18 29.61 36
LSA1SA LS1A04 LSA1SA
550 1500 500
15731 9936 13906
339 43 116
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LSM12
2.5
6791
69
LSM12 LSM12 LSM12
4.5 7.1 3.6
10687 15406 11127
343 91 179
15805
102
12200
175
8303
103
Luminex kit (lot)
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
Luminex kit (lot) Cut-off value Control bead Control bead MFI MFI IgG IgG Positive Negative
LS1PRA LSA1SA
1000 1500
8522 13480
393 124
LSA1SA
LMX
1
19557
123
Lab no.
48 L 51 54 58 62 100 112 114 116 117 119 120 133
L L L L L L L L L L L L
136 142 143 145 149 157 160
C, L L L L L L L
162 165 169 181 185 194 195 197 206 212 214
L L L L L C, L L L C, L L L
EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA EDTA, Adsorption Beads Heat Inactivation EDTA EDTA EDTA
EDTA EDTA EDTA EDTA Heat Inactivation
NO NO NO NO NO NO NO
18
NO NO NO NO NO NO NO
18 19 18 18 18 19
NO
19
NO NO NO NO NO NO NO NO NO NO NO NO
NO NO NO NO NO EDTA NO Adsorption NO Beads EDTA NO NO NO NO EDTA NO EDTA NO
229 230 L 232 L 242 L 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L L C, F, L L L L L L L L L L L
In House 19 18 19 19
A*68:02
A*24:03
B*51:02 C*05:01
18 18 19 3006187 3005724 18 18 17
C*03:02
3005724
A*32:01, B*15:01/02/03/13/16/18, B*35:01/08, B*38:01, B*44:03, B*49:01, B*50:01, B*51:01, B*52:01, B*53:01, B*56:01, B*57:01, B*58:01, B*59:01
15
C*03:02
18 17
CW*03:02
EDTA
EDTA
B*13:02 18
NO YES
216 L 218
222 F 227 L
18 18 18
3005464
EDTA, Dilution
A*32:01, B*15:01/15:02/15:03/15:13/1 5:16/15:18, B*35:01/35:08/49:01/50:01/5 1:01/52:01/53:01/56:01/57:0 1/58:01/59:01
LM1 A*32:01, B*13:02, LSA I&II SA B*15:01/B62, B*15:02/B75, B*15:03/B72, B*15:13/B77, B*15:16/B63, B*15:18/B71, B*35:01, B*35:08, B*38:01, B*40:02/B61B*41:01, B*44:02, B*44:03, B*45:01, B*47:01, B*49:01, B*50:01, B*51:01, B*52:01, B*53:01, B*56:01, B*57:01, B*58:01, B*59:01, B*78:01, B*40:01
Adsorption Beads
EDTA EDTA EDTA
EDTA
LSA1SA
750
LSM12 LSM12
1.5
11486
44
LSM12
3
9714
50
LM1
2
21871
175
LS1PRA
2000
9371
84
LSM12
2.5
11487
47
12891
89
NO NO NO
EDTA EDTA
LSA1SA
1500
B*15 NO NO NO NO NO NO NO NO NO NO NO
19
C*03:02 B*51:01
18
18 3006015
NEQ‐119
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Othe
Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 29 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A1 Consensus Absent 4.1% % reported Lab no. spec tech 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
A1
L
< 2000
A1
L
< 2000
A1
L
A24 Not Assessed 17.8% spec
tech
MFI
A24
L
< 2000
A24 A24
L L
< 2000 < 2000
< 2000
A24
L
< 2000
A24
L
< 2000
A24
L
< 2000
A24
L
A24 A24
L L
A24 A24
L L
A24
L
A24
L
A2403 Not Assessed 45.2% spec A2403 A2403 A2403
L L L
A2403 A2403 A2403 A2403
L L L L
A2403 A2403
L L
A2403
L
A2403 A2403
L L
A2403
L
A2403
L
A2403
L
A2403 A2403 A2403
L L L
A2403
L
A2403 A2403 A2403 A2403 A2403
L L L L L
A2403
L
tech
< 2000 < 2000 2000-5000
< 2000 < 2000
< 2000
A2403
L
A2403
L
A2403
L
A2403 A2403 A2403 A2403
L L L L
A2403
L
< 2000
MFI
A25 Present 95.9% spec
< 2000 < 2000 < 2000
tech
MFI
A25 A25 A25 A25 A25 A25 2000-5000 A25 < 2000 A25 < 2000 < 2000 A25 A25 2000-5000 A25 < 2000 A25 A25 A25 A25 A25 < 2000 A25 A25 A25 < 2000 A25 < 2000 A25 A25 A25 A25 A25 A25 < 2000 A25 A25 < 2000 A25 A25 A25 < 2000 A25 A25 A25 < 2000 A25 < 2000 A25 < 2000 A25 A25 < 2000 A25 A25 < 2000 A25 < 2000 A25 < 2000 A25 < 2000 A25 < 2000 A25 A25 < 2000 A25 A25 A25 A25 < 2000 A25 A25 < 2000 A25
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L L L L L L L L L L L. L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A25 A25 < 2000 A25 A25 A25 A25 < 2000 A25 < 2000 A25 < 2000 A25 2000-5000 A25 A25 A25 A25 < 2000 A25 A25 A25 A25
L L L L L L L L L L L L L L L L L
A26 Present 95.9% spec A26 A26 A26 A26 A26 A26 A26 A26
tech
MFI
A34 Present 93.2% spec
tech
MFI
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A34 A34 A34 A34 A34 A34 A34 A34
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 > 5000 A26
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L C, L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000
A34 A34 > 5000 A34
L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A34 A34 A34
L L L
A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34 A34
L L L L L L L L L L L L L
A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26 A26
A66 Present 95.9% spec A66 A66 A66 A66 A66 A66 A66 A66
tech
MFI
A11 Present 93.2% spec
tech
MFI
A29 Present 94.5% spec
tech
MFI
A30 Present 83.6% spec
tech
MFI
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A29 A29 A29 A29 A29 A29 A29 A29
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000
A30 A30 A30 A30 A30 A30 A30 A30
L L L L L L L L
> 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000
A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 A66 > 5000 A66 > 5000 A66 > 5000 A66 > 5000 A66 2000-5000 A66 2000-5000 A66 A66 2000-5000 A66 A66 > 5000 A66
L L L L L L L L L L L L L L L L L L L L L L L C, L L L L L L L L L L L L L L L L L L L L F L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000
A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000
A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29 A29
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 < 2000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 < 2000 > 5000 2000-5000 > 5000 > 5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000
A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30
L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 2000-5000 < 2000, 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 > 5000 2000-5000 2000-5000 > 5000
A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30
L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 2000-5000, > 5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 >5000 2000-5000
A30
L
2000-5000
A30
L
< 2000
A11 A11 A11
L F L
2000-5000 A29 A29 > 5000 A29
L F L
< 2000 A30
L
> 5000
2000-5000 A66 > 5000 A66 > 5000 A66 A66 2000-5000 A66 > 5000 A66 > 5000 A66 > 5000 A66 > 5000 A66 > 5000 A66 > 5000 A66 2000-5000 A66 2000-5000 A66 > 5000 A66 2000-5000 A66 > 5000 A66 2000-5000 A66
L L L L L L L L L L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000
A11 A11 A11
L L L
< 2000 2000-5000 < 2000 2000-5000 < 2000 > 5000 > 5000
L L
2000-5000 < 2000
L L L L L L L L L L L L L
L L L L L L L L L L L L L L L L L
A30 A30
A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11 A11
2000-5000 A29 > 5000 A29 > 5000 A29 A29 2000-5000 A29 > 5000 A29 > 5000 A29 > 5000 A29 > 5000 A29 > 5000 A29 > 5000 A29 2000-5000 A29 2000-5000 A29 > 5000 A29 2000-5000 A29 > 5000 A29 2000-5000 A29
A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30 A30
L L L L L L L L L L L L
< 2000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 > 5000
> 5000
> 5000
2000-5000 > 5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000 < 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other Number Total number
3 73
< 2000 3 2000-5000 0 > 5000 0
13 73
< 2000 12 2000-5000 1 > 5000 0
33 73
< 2000 30 2000-5000 3 > 5000 0
70 73
< 2000 0 2000-5000 0 > 5000 68
70 73
< 2000 0 2000-5000 0 > 5000 68
68 73
< 2000 0 2000-5000 13 > 5000 52
70 73
< 2000 0 2000-5000 4 > 5000 64
68 73
< 2000 0 2000-5000 15 > 5000 51
69 73
< 2000 15 2000-5000 38 > 5000 14
61 73
< 2000 10 2000-5000 29 > 5000 20
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 30 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment A31 Conse Present % rep 89.0% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
A31 A31 A31 A31 A31 A31 A31 A31
L L L L L L L L
MFI
A32 Absent 1.4% spec
tech
MFI
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 > 5000 > 5000 A32
A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31
L L L L L L L L L L L L L L L L L L L L L L
2000-5000 < 2000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31
L L L L L L L L L L L L L L
2000-5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000
A31 A31 A31
L L L
2000-5000 2000-5000 < 2000
A31 A31 A31
L F L
< 2000
A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31 A31
L L L L L L L L L L L L L L L
2000-5000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000 < 2000 2000-5000 < 2000 2000-5000
L
2000-5000
A33 Present 93.2% spec
tech
MFI
A33 A33 A33 A33 A33 A33 A33 A33
L L L L L L L L
> 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000
A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 > 5000 > 5000 2000-5000, > 5000 > 5000 < 2000 > 5000 2000-5000 > 5000 2000-5000, > 5000 < 2000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 < 2000
A33 A33 A33
L F L
< 2000
A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33 A33
L L L L L L L L L L L L L L L L
A74 Absent 2.7% spec
tech
MFI
A68 Present 94.5% spec
tech
MFI
A69 Not Assessed 71.2% spec
tech
MFI
A36 Not Assessed 47.9% spec
A68 A68 A68 A68 A68 A68 A68 A68
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000
A69 A69 A69 A69 A69 A69 A69 A69
L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000
A36 A36 A36
L L L
A36 A36
A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 < 2000 A68 A68
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 2000-5000 > 5000 > 5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 > 5000 > 5000 > 5000 < 2000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 2000-5000 2000-5000
A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69 A69
L L L L L L L L L L L L L L L L L L L L L L
2000-5000 < 2000 > 5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000
A69 A69 A69 A69 A69 A69
L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000
A69
L
A69 A69
L L
2000-5000 A36 2000-5000 A36
L L
A69 A69
L L
2000-5000 A36 2000-5000 A36
A69
L
2000-5000 A36
L F L
2000-5000
> 5000
A68 A68 A68
2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000 > 5000 < 2000
A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68 A68
L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 < 2000 2000-5000 > 5000 2000-5000 > 5000 < 2000
tech
MFI
A43 Present 84.9% spec
tech
MFI
A80 Absent 1.4% spec
L L
< 2000 A43 < 2000 A43 2000-5000 A43 A43 A43 A43 2000-5000 A43 < 2000 A43
L L L L L L L L
> 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
A36
L
< 2000
A36 A36
L L
A36
L
A36 A36 A36
L L L
A36
L
A36
L
A36 A36
L L
A36 A36 A36 A36
L L L L
A36
L
2000-5000 A36
L
L L
A43 A43 2000-5000 A43 < 2000 A43 A43 A43 A43 A43 < 2000 A43 A43 A43 < 2000 A43 < 2000 A43 < 2000 A43 A43 < 2000 A43 A43 A43 < 2000 A43 A43 < 2000 A43 < 2000 A43 A43 < 2000 A43 < 2000 A43 2000-5000 A43 < 2000 A43 A43 < 2000 A43 A43 < 2000 A43 A43 < 2000 A43 < 2000 A43 A43 < 2000 A43 < 2000 A43
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
> 5000 > 5000 > 5000 A80 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000
L
< 2000
A43
L
> 5000
A43
L
2000-5000
A43
L
> 5000
A43 A43
L L
> 5000 >5000
A43 A43 A43 A43 A43 A43 A43 A43
L L L L L L L L
2000-5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 2000-5000
A43 A43 A43 A43
L L L L
> 5000 2000-5000 > 5000 2000-5000
tech
MFI
> 5000
A74
L
A74
F
> 5000
A69
L
A36 2000-5000 A36
F L
A69
L
2000-5000
A69 A69 A69 A69 A69 A69
L L L L L L
2000-5000 2000-5000 < 2000 2000-5000 2000-5000 < 2000
A36 A36 A36 A36
L L L L
< 2000 < 2000 < 2000 < 2000
A69
L
2000-5000 A36
L
< 2000
A69
L
2000-5000 A36
L
< 2000
< 2000
L
B51 Absent 2.7% spec
tech
B51
L
B51
F
MFI
> 5000
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 65 73
< 2000 14 2000-5000 45 > 5000 5
1 73
< 2000 0 2000-5000 0 > 5000 1
68 73
< 2000 9 2000-5000 28 > 5000 30
2 73
< 2000 1 2000-5000 0 > 5000 0
69 73
< 2000 3 2000-5000 19 > 5000 45
52 73
< 2000 10 2000-5000 40 > 5000 2
35 73
< 2000 30 2000-5000 4 > 5000 0
62 73
< 2000 0 2000-5000 7 > 5000 53
1 73
< 2000 1 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 1
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 31 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B5102 Conse Absent % rep 1.4% tech MFI Lab n spec 9 11 12 14 15 19 20 23 24 B5102 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L
B52 Absent 4.1% spec
> 5000 B52
tech
L
MFI
B7 Absent 1.4% spec
L
B52
F
MFI
> 5000
B44 Absent 4.1% spec
B44
B7 B52
tech
L
2000-5000
tech
L
MFI
> 5000
B45 Absent 2.7% spec
B45
tech
L
MFI
B13 Present 84.9% spec
tech
MFI
B13 B13 B13 B13 B13 B13 B13 B13 2000-5000 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L
2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 > 5000 > 5000 > 5000 2000-5000
B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13 B13
L L L L L L L L L L L L L L
B64 Absent 4.1% spec
tech
MFI
B65 Absent 4.1% spec
tech
MFI
L
2000-5000
B45 B44
L
F
tech
MFI
B63 Not Assessed 43.8% spec
tech
MFI
B63
L
2000-5000
B63
L
2000-5000
B63
L
2000-5000
> 5000 B63 B63
L L
> 5000 < 2000
> 5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000, > 5000 2000-5000
B63 B63
L L
2000-5000 < 2000
B63
L
< 2000
B63
L
< 2000
B63 B63 B63
L L L
2000-5000 < 2000 < 2000
B63
L
< 2000
B63 B63
L L
< 2000 < 2000
2000-5000 2000-5000 > 5000 2000-5000 < 2000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 2000-5000 < 2000 2000-5000 2000-5000
B63 B63
L L
< 2000 < 2000
B63 B63 B63
L L L
< 2000 < 2000 < 2000
B63
L
< 2000
B63 B63 > 5000 B63 B63
L L L L
< 2000 < 2000 > 5000 < 2000
B63 B63
F L
< 2000
B63 B63 B63 B63
L L L L
< 2000 < 2000 < 2000 < 2000
B63
L
< 2000
B62
> 5000 B44
B62 Absent 4.1% spec
B13 B13 B13
L L L
2000-5000 2000-5000 < 2000
B13 B13
F L
2000-5000
2000-5000 B13 B13
L L
2000-5000 < 2000
B13 B13 B13 B13 B13 B13 B13
L L L L L L L
2000-5000 > 5000 2000-5000 2000-5000 > 5000 2000-5000 < 2000
B13 B13 B13
L L L
2000-5000 < 2000 2000-5000
B64
L
2000-5000 B65
L
B64
F
B65
F
B64
L
B65
L
< 2000
L
B62
L
B62
F
2000-5000
2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 0 > 5000 1
3 73
< 2000 0 2000-5000 1 > 5000 1
1 73
< 2000 0 2000-5000 0 > 5000 1
3 73
< 2000 0 2000-5000 2 > 5000 1
2 73
< 2000 0 2000-5000 1 > 5000 0
62 73
< 2000 9 2000-5000 43 > 5000 8
3 73
< 2000 1 2000-5000 1 > 5000 0
3 73
< 2000 0 2000-5000 2 > 5000 0
3 73
< 2000 0 2000-5000 0 > 5000 2
32 73
< 2000 24 2000-5000 5 > 5000 2
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 32 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B75 Not Assessed Conse % rep 12.3% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B76 Not Assessed 5.5% spec
B75
L
< 2000
B75
L
2000-5000 B76
B75
L
> 5000
B76
B75
L
< 2000
B76
B75
L
< 2000
tech
MFI
B77 Not Assessed 8.2% spec
tech
MFI
B38 Absent 4.1% spec
B77
L
< 2000
L
< 2000 B77
L
< 2000
L
< 2000 B77
L
> 5000 B38
L
< 2000 B77
L
< 2000
tech
L
MFI
B39 Absent 2.7% spec
tech
> 5000
MFI
B57 Absent 4.1% spec
B57
tech
L
MFI
B58 Not Assessed 6.8% spec
> 5000 B58
tech
L
MFI
B18 Absent 1.4% spec
L
> 5000
B75
L
2000-5000
B75
F
B75
L
B76
L
> 5000
B38 B77
L
L
B38 2000-5000
B77
L
> 5000 B39
L
2000-5000 B57
L
> 5000
F
B39
F
B57
F
> 5000
MFI
> 5000
B18
B75
tech
> 5000 B58
L
> 5000
B58
L
2000-5000
B58
F
B58
L
L
2000-5000
B49 Not Assessed 5.5% spec
tech
MFI
B49
L
> 5000
B49
L
2000-5000
B49
F
B49
L
B50 Absent 1.4% spec
B50
tech
L
MFI
> 5000
< 2000
2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 9 73
< 2000 3 2000-5000 3 > 5000 2
4 73
< 2000 3 2000-5000 0 > 5000 1
6 73
< 2000 3 2000-5000 0 > 5000 3
3 73
< 2000 0 2000-5000 0 > 5000 2
2 73
< 2000 0 2000-5000 1 > 5000 0
3 73
< 2000 0 2000-5000 0 > 5000 2
5 73
< 2000 0 2000-5000 2 > 5000 2
1 73
< 2000 1 2000-5000 0 > 5000 0
4 73
< 2000 0 2000-5000 2 > 5000 1
1 73
< 2000 0 2000-5000 0 > 5000 1
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 33 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B54 Conse Absent % rep 2.7% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 B54 218 222 227 229 230 B54 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
B55 Absent 4.1% spec
B55
tech
L
MFI
< 2000
B56 Absent 4.1% spec
B56
L
B56 L
2000-5000 B55
L
tech
L
2000-5000
MFI
B27 Absent 4.1% spec
tech
MFI
> 5000
> 5000
B35 Absent 1.4% spec
B35
tech
L
MFI
B37 Absent 2.7% spec
> 5000 B37
L
2000-5000 B55
L
2000-5000 B56
L
MFI
B60 Not Assessed 9.6% spec
tech
MFI
MFI
B61
L
< 2000
B41 Absent 2.7% spec
L
< 2000
B61
L
< 2000
L
2000-5000 B61
L
2000-5000 B41
B60
L
< 2000
B61
L
< 2000
B61
L
< 2000
B60
L
> 5000
> 5000
B60
L
> 5000
B27
L
> 5000
B60
L
2000-5000
L
tech
B60
L
2000-5000 B27
B61 Not Assessed 6.8% spec
< 2000 B60
B27
B37 L
tech
tech
L
B41
L
F
> 5000
B60
L
MFI
B46 Not Assessed 6.8% spec
tech
MFI
2000-5000 B46
L
< 2000
B46
L
< 2000
B46
L
2000-5000
B46
F
B46
L
< 2000
2000-5000
< 2000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 2 73
< 2000 0 2000-5000 2 > 5000 0
3 73
< 2000 1 2000-5000 2 > 5000 0
3 73
< 2000 0 2000-5000 1 > 5000 2
3 73
< 2000 0 2000-5000 0 > 5000 3
1 73
< 2000 0 2000-5000 0 > 5000 1
2 73
< 2000 1 2000-5000 0 > 5000 0
7 73
< 2000 3 2000-5000 2 > 5000 2
5 73
< 2000 4 2000-5000 1 > 5000 0
2 73
< 2000 1 2000-5000 1 > 5000 0
5 73
< 2000 2 2000-5000 2 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 34 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B47 Conse Absent % rep 1.4% tech Lab n spec 9 11 12 14 15 19 20 23 24 B47 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 214 216 218 222 227 229 230 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
L
MFI
B48 Absent 2.7% spec
tech
MFI
2000-5000
B53 Absent 2.7% spec
B53
B48
L
tech
L
MFI
B59 Absent 4.1% spec
> 5000 B59
tech
MFI
L
B67 Absent 2.7% spec
> 5000
2000-5000 B67
B48
tech
F
B53
F
B59
F
B59
L
L
2000-5000 B67
L
MFI
B71 Not Assessed 13.7% spec
tech
MFI
B71
L
< 2000
B71
L
2000-5000
B71
L
> 5000
B71
L
< 2000
B71
L
< 2000
B71
B72 Absent 4.1% spec
tech
MFI
B72
L
> 5000
L
< 2000
L
> 5000
B71
L
2000-5000 B72
2000-5000 B71
L
2000-5000
B71
F
2000-5000 B71
L
B72
F
B73 Absent 1.4% spec
tech
MFI
B78 Absent 2.7% spec
B78
B73
F
tech
L
B78
F
MFI
B81 Absent 2.7% spec
tech
MFI
2000-5000
B81
L
B81
F
> 5000
2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 1 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 1
3 73
< 2000 0 2000-5000 1 > 5000 1
2 73
< 2000 0 2000-5000 2 > 5000 0
10 73
< 2000 4 2000-5000 4 > 5000 1
3 73
< 2000 0 2000-5000 0 > 5000 2
1 73
< 2000 0 2000-5000 0 > 5000 0
2 73
< 2000 0 2000-5000 1 > 5000 0
2 73
< 2000 0 2000-5000 0 > 5000 1
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 35 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 HLA specificity for assessment B82 Conse Absent % rep 2.7% tech Lab n spec 9 11 12 14 15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48 51 54 58 62 100 112 114 116 117 119 120 133 136 142 143 145 149 157 160 162 165 169 181 185 194 195 197 206 212 B82 214 216 218 222 227 229 230 B82 232 242 252 267 268 273 277 284 292 293 294 302 303 309 351 361 392
MFI
Cw1 Not Assessed 45.2% spec
tech
MFI
Cw1 Cw1
L L
2000-5000 < 2000
Cw1 Cw1
L L
2000-5000 2000-5000
Cw9 Absent 4.1% spec
Cw9
L
L
tech
L
MFI
< 2000
Cw10 Absent 1.4% spec
Cw10
tech
MFI
L
Cw5 Absent 2.7% spec
< 2000 Cw5
tech
L
MFI
Cw12 Not Assessed 28.8% spec
tech
MFI
Cw14 Absent 1.4% spec
tech
MFI
Cw15 Not Assessed 19.2% spec
tech
MFI
Cw12 Cw12
L L
< 2000 < 2000
Cw15 Cw15
L L
< 2000 < 2000
Cw12
L
2000-5000
Cw15
L
< 2000
Cw15
L
< 2000
L
< 2000
Cw1 Cw1
L L
2000-5000 < 2000
Cw12
L
< 2000
Cw1
L
< 2000
Cw12
L
< 2000
Cw1
L
< 2000
Cw12
L
< 2000
Cw15
L
< 2000
Cw1
L
< 2000
Cw12
L
< 2000
Cw15
L
< 2000
Cw1
L
<2000
Cw1 Cw1 Cw1 Cw1
L L L L
2000-5000 < 2000 2000-5000 < 2000
Cw12
L
< 2000
Cw15
L
< 2000
Cw12 Cw12
L L
< 2000 < 2000
Cw15 Cw15
L L
< 2000 < 2000
Cw1 Cw1 Cw1 Cw1
L L L L
< 2000 < 2000 2000-5000 < 2000
Cw12
L
< 2000
Cw12
L
2000-5000
Cw15
L
2000-5000
Cw1 Cw1 Cw1
L L L
< 2000 <2000 < 2000
Cw12
L
< 2000
Cw12
L
< 2000
Cw1 Cw1
L L
< 2000 < 2000
Cw12
L
< 2000
Cw1 Cw1
L L
< 2000 < 2000
Cw1
L
2000-5000
Cw12
L
< 2000
Cw15
L
< 2000
Cw15
F
Cw15
L
< 2000
Cw15
L
< 2000
Cw9
L
Cw9
F
tech
MFI
Cw18 Absent 1.4% spec
tech
MFI
< 2000
Cw1
2000-5000
Cw16 Absent 1.4% spec
2000-5000
Cw1
L
< 2000
Cw5
F
Cw12 Cw12
F L
< 2000
Cw14
Cw1 Cw1 Cw1 Cw1
L L L L
2000-5000 < 2000 < 2000 2000-5000
Cw12 Cw12 Cw12
L L L
< 2000 < 2000 2000-5000
Cw1
L
< 2000
F
Cw16
F
Cw18
F
2000-5000
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other 2 73
< 2000 0 2000-5000 2 > 5000 0
33 73
< 2000 21 2000-5000 10 > 5000 0
3 73
< 2000 1 2000-5000 1 > 5000 0
1 73
< 2000 1 2000-5000 0 > 5000 0
2 73
< 2000 1 2000-5000 0 > 5000 0
21 73
< 2000 17 2000-5000 3 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
14 73
< 2000 12 2000-5000 1 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
1 73
< 2000 0 2000-5000 0 > 5000 0
NEQ‐119 Issue 2
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 36 of 37 Effective Date 13/10/16
UK NEQAS for H&I ‐ SCHEME 3 ‐ HLA ANTIBODY SPECIFICITY ANALYSIS CLASS I HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018 DESPATCHED ON 17 APRIL 2018 Techniques used IgG
Sample Treatment IgG
High Background
9 11 12 14
L L L L
EDTA NO EDTA NO EDTA EDTA, Heat NO Inactivation
15 19 20 23 24 25 26 28 34 35 38 39 41 42 45 48
L L C, L L L L L L L L L L L L L L
Neg control serum batch
Allele Specific Antibodies
Luminex kit (lot)
Cut-off value
IgG
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
LS1A04
1000
10000
71
B*40:06, B*15:02
LS1A04 LS1A04
500 1500
11023 14005
67 19
LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1266 500 1055/955 1000
9710 11321 12922 11099 11003 10808 11545 10252 11491 12099 10520 10810 7814 12578 13500
45 39 43 18 50 53 32 86 15 16 24 73 14 114 40
Luminex kit (lot)
Cut-off value
Control bead MFI Negative
Cut-off value
IgG
IgG
Control bead MFI Positive
Control bead MFI Negative
Luminex kit (lot)
IgG
Control bead MFI Positive
Luminex kit (lot)
IgG
IgG
IgG
Cut-off value Control bead MFI Positive
Control bead MFI Negative
LSM12 LSM12 LSM12
4.5 7.1 3.6
10425 15836 12168
249 132 159
LS1PRA LSA1SA
1000 1500
9327 12448
148 120
LSA1SA
1500
107
16275
114
LSA1SA
2
16232
146
Lab no.
51 54 58 62 100 112 114 116 117 119 120 133
L L L L L L L L L L L L
136 142 143 145 149 157 160
C, L L L L L L L
162 165 169 181 185 194 195 197 206 212 214
L L L L L C, L L L C, L L L
EDTA EDTA EDTA EDTA EDTA EDTA
NO NO NO NO NO NO NO
EDTA NO EDTA NO EDTA NO EDTA NO EDTA NO EDTA NO EDTA, AdsorNO Heat NO Inactivation EDTA EDTA EDTA
EDTA EDTA
NO NO NO NO NO NO NO NO NO
EDTA EDTA NO Heat NO Inactivation
EDTA
EDTA Adsorption Beads EDTA
EDTA EDTA
NO NO NO NO NO NO NO NO NO NO NO NO
222 F 227 L
252 267 268 273 277 284 292 293 294 302 303
L L C, L L L L L L L L L
309 L 351 L 361 L 392
18 4 In House 19 18 19 19 18 19 18 18 18 19
B*15:02, B*40:06
A*24:03
A*24:03
EDTA
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LSA1SA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
1300 1000 1000 >1500 541 500 1000 1000 500 1000 500
12524 8876 11904 13311 12842 16783 6213 8185 10052 9839 9002 11503
47 72 36 39 166 309 29 127 23 22 14 134
LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA LS1A04 LS1A04
1000 1000 1000 1000 1000 1000 1000
16239 9891 1910 11819 22950 7462 7824
62 19 361 20 357 37.68 16.4
LS1A04 LS1A04 LS1A04 LS1A04 LM1 LS1A04 LS1A04
1000 85 1000 500 2 1000 1000
11212 6306 3336 10188 19213 12074 8923
19 73 20 30 232 17 81
LS1A04 LM1 A*11:01/11:02/25:01/26:01/29 LSA1SA :01/29:02/30:01/31:01/33:01/3 3:03/34:02/43:01/66:01/66:02/ 68:01/68:02 B*13:02
1000 1000 750
11539 21124 12187
19 85 172
LM1 LSA I&II SA
3000
18316 15174
169 225
LM1 LS1A04 LSA1SA
1000 1200
>10000 7530 17541
37 11 133
LM1 LSA1SA LS1PRA LS1A04 LS1A04 LS1A04 LS1A04 LS1A04 LSA1SA
2 500 2000 1500 500 1000 500 500
20632 13486 8094 11313 8206 8338 9617 7909 12222
150 205 100 28 48 18.29 29 27.5
18
LS1A04
1000
8644
60
18 3006015
LSA1SA LS1A04 LSA1SA
500 1500 500
13456 9661 14956
46 54 105
18 18 19 3006187 3005724 18 18
3005724
A*24:03 A*24:03 A*11:01, A*25:01, A*26:01, A*29:02, A*33:03, A*34:02, A*43:01, A*66:01, A*66:02, A*68:01, A*68:02
15 18 17
18
NO YES
3005464 A*11:01 A*11:02 A*24:03 A*25:01 A*26:01 A*9:01 A*29:02 A*31:01 A*33:01 A*33:03 A*34:02 A*43:01 A*66:01 A*66:02 A*68:01 A*68:02 EDTA, Dilution
3006081 18
Adsorption Beads
EDTA EDTA EDTA
NO NO NO NO NO NO NO NO
EDTA, Heat NO Inactivation
EDTA
LSA1SA
7174
115
LSM12
1.5
12245
44
LSM12
3
8125
42
LMX
1
18823
128
LS1A04
2000
11386
11
LSM12
2.5
10713
38
LSM12
NO
NO NO
EDTA EDTA
1460 2000 500 1500
13275
19
NO
216 L 218
229 230 L 232 L 242 L
18 18 18
NO NO NO
19 18
NEQ‐119
Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other
Issue 2 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H&I
P 37 of 37 Effective Date 13/10/16
